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ABSTRACT
This thesis describes a study of the antigenicity 
of pig heart citrate synthase (PHCS).
Following immunisation with PHCS,11 mouse 
monoclonal antibodies (mAbs) were raised against this 
enzyme,two of IgG1 type,and nine of IgM type.
An investigation was performed into the 
effectiveness of a variety of solid-phase immunoassay, 
systems in the detection of mAbs. This work showed that 
a sandwich ELISA was the most effective assay for detect­
ing all of a library of mAbs raised against PHCS.
Epitope mapping studies performed on fragments 
of PHCS (produced by enzymic and chemical cleavage) have 
shown that mAbs B and C recognise an epitope between 
residues 258-313,and mAb E recognises an epitope between 
residues 1-230. Further studies using a synthetic 
peptide have shown that the epitopes recognised by 
mAbs B and C lie between residues 288-302.
Methods to predict potential antigenic regions 
including use of hydrophilicity data,atomic mobility 
values,composite surface profile and protrusion indices 
were applied to PHCS. All four methods indicated that 
a possible antigenic site should exist at the experim­
entally determined epitope between residues 288-302 of 
PHCS. This correlation confirms the ability of these 
predictive methods to indicate possible antigenic sites.
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21.0 General Introduction
A current major area of research in immunology 
is the study of the antigenicity of proteins. At 
present the directions of this study are towards:
a) experimentally determining the structures 
and amino acid compositions of individual antigenic 
determinants
b) devising computer programmes to predict 
which segments of protein molecules will be involved 
in antigenic determinants
c) using chemically synthesised immunogens to 
initiate the production of antibodies or activated
T cells which can react with larger antigens.
A detailed study of the specificities and 
affinities of antibodies for antigenic determinants will 
help us to choose the best antibodies for use as tools 
in sensitive immunoassays, affinity purification 
procedures and to evaluate their use for in vivo drug 
targetting. The ability to predict and chemically 
synthesise antigenic sites for use as immunogens may 
lead to their general use in vaccine production.
Only a limited number of proteins have so far 
been studied by these methods.
This project is concerned with the study of the 
antigenic determinants of citrate synthase, using 
monoclonal antibodies and experimental analyses of 
antigenic sites. Results are compared with computer 
predictions of the antigenic determinants for the enzyme.
3Citrate synthase is a well characterized 
protein and provides an ideal subject by which to 
increase the overall database of information on protein 
antigenic structures.
1.1 The Immune Response
The site on an antigen to which an antibody 
binds is called the antigenic determinant (also called 
an epitope, or antigenic site).
Immunogenicity is a term used to describe the 
ability of an antigen to elicit a response, following 
immunisation, generating antibodies and activated T cells 
The antigenicity of a protein is its ability to be 
recognised by the product of a previous response, by 
antibodies or T cells. Any antigen which is immunogenic 
must be antigenic. However, some low molecular weight 
substances, such as drugs, hormones and other small 
molecules are unable to stimulate a primary response 
and are thus non-immunogenic unless conjugated to larger 
'carrier' molecules; such substances are termed 'haptens' 
The haptens alone, however, are able to react with the 
resultant antiserum, or sensitized cells, and are 
therefore antigenic.
An immune response leading to the production of 
antibodies has two phases;
1) the recognition of the antigen as foreign, a function 
which is usually fulfilled by T lymphocytes and 
macrophages.
2) the effector phase in which -antibodies are produced 
and the antigen eliminated.
Very few antigens bind directly to antigen- 
reactive T cells or B cells, rather they are usually 
presented on the surface of antigen presenting cells 
(APCs). APCs include dendritic cells, which are non-
5phagocytic, and macrophages, which are phagocytic. Thus 
the antigen may be presented to T and B cells as a 
native, or partially denatured antigen.
Each B cell is committed to the production of 
antibodies with a unique combining site which binds 
to one epitope only. During antigen presentation the B 
cell recognises the antigen through its receptor and 
proliferates into both memory cells and antibody-secreting 
plasma cells. This proliferation of one cell leading to 
the production of a population of cells is called clonal 
expansion. T cells do not secrete antibodies, but as do 
B cells, they have surface receptors to specific antigenic 
epitopes and are similarly expanded clonally. Helper T 
cells which have responded to antigen presented by 
APCs subsequently activate B cells, already committed 
to the same antigen, into antibody production. This 
effect is balanced by suppressor T cells, which appear 
to be able to bind specific antigens directly, without 
the need for APCs, and subsequently inhibit T-helper 
cells, rather than acting directly on B cells. These 
regulatory T cells appear to exert this control of the 
production of antibody by B cells through the release 
of soluble mediating factors.
1. 2 Protein Antigenic Structure
This section describes the discovery of 
different types of antigenic determinants, using 
experiments employing serum antibodies.
Early workers used peptide fragments to study 
protein immunochemistry. As early as 1942, Landsteiner 
showed how peptides from silk fibroin were able to 
inhibit the reaction of the latter with its antibodies.
Work by the group of Atassi from 1963-1975 led 
to the elucidation of the first complete antigenic 
structure of a protein, that of sperm whale myoglobin 
(swMb). This same group also determined the antigenic 
sites of hen egg lysozyme (Atassi , 1978), serum albumen 
(Atassi, 1982) and human adult haemoglobin (Hb) (Atassi, 
1984). Due to the complexity of protein structure, 
the antigenic sites cannot be determined by the exclusive 
application of a single approach. Atassi, 1975, developed 
a strategy consisting of five approaches. These are:
1) The determination of the influence of 
conformational changes on the immunochemical behaviour 
of the protein
2) The study of the immunochemistry of specific 
chemically modified derivatives of the protein
3) The isolation and the study of a large 
number of overlapping peptide fragments to identify 
immunochemically-reactive fragments that can quantitative 
account for the total anti-protein antibodies
4) The study of the immunochemistry and 
conformation of specific chemical derivatives of
7immunochemically reactive peptides.
5) The synthesis, chemically, of the reactive 
regions defined by methods 1-4, and verification of 
the antigenic activity of these peptides.
Thus, determination of the antigenic structures of 
swMb and lysozyme has defined the problems involved in 
precise delineation of two types of antigen sites for 
subsequent workers studying protein antigenicity.
1.2.1 Determination of the antigenic structure of 
sperm whale myoglobin
Sperm whale myoglobin is a protein of 153 
amino acids folded in a helical compact structure, 
carrying 1 haem group.
Conformational changes in swMb caused by 
inclusion of modified haem groups, or modification of 
side chains were shown to influence antigenic activity 
(Andres a.r>d Atassi,1970) . A series of well purified 
derivatives modified at a total of 23 amino acid sites 
gave an initial indication of the location of some 
of the amino acids needed for antibody binding. However, 
care was needed to ensure that a resultant decrease in 
antibody binding following modification was directly 
due to alteration of an essential antigenic site residue 
and not caused indirectly by a conformational change 
(Atassi and Thomas, 1969; Atassi, 1975).
Peptide fragments of swMb and derivatives of
8the same were tested for their ability to react with 
antisera raised against the native swMb (Singhal a-nd 
f\fca^ slr 1971; Atassi, 1975). Following this initial 
description of the epitopes, synthetic peptides 
corresponding to these regions were tested for their 
ability to inhibit immunoprecipitation of the native 
swMb by antisera (Pai and Atassi, 1975; Kokotsu and f)tass,L>, 
1974) .
By this method native swMb was shown to have 
5 major antigenic sites, each consisting of a linear 
amino acid sequence, seen to be sequentially linked by 
peptide bonds. This type of antigenic site is termed 
'continuous' (also termed a linear epitope). Two of 
the sites exhibit degrees of shift or displacement and 
minor variability in size (limited to + 1 residue only) 
from one antiserum to the next. The sites contain 
6-7 residues and are between 1.9-2.3nm in their extended 
dimensions (Atassi, 1984). The size, surface locations 
and shape of these antigenic sites make them quite 
accessible for binding with antibody combining sites.
Due to their content of hydrophilic residues (lysine, 
arginine, aspartate, glutamate and histidine), it 
was concluded that the interaction with antibodies must 
be predominantly polar in nature. Other stabilizing 
effects are contributed by hydroxy and non-polar amino 
acids through hydrogen bonding and hydrophobic 
interactions (Atassi, 1984).
The same five antigenic sites of sw myoglobin 
are recognised by rabbit, goat, chicken, cat, pig and 
mouse antisera (Twining et al, 1980).
91.2.2 Determination of the antigenic structure of 
Hen Egg Lysozyme
Hen egg lysozyme is of a different structural 
type when compared to Mb. It has 129 amino acid residues 
and is held together in a tight conformation by 4 
internal disulphide crosslinks. Lysozyme has 25% of its 
residues forming ec-helices, as compared to 70% for 
myoglobin.
Initial work using the previously proposed 
strategy proved difficult, partly due to the tight 
conformation making specific cleavage to fragments 
unreliable and partly due to the apparent need for 
the disulphide bonds to be intact in order to retain 
antigenicity (Lee and Afcas&i, 1973 ; HabeebcxrvJi. ftbassi,19 71cd.
This initial work predicted 3 antigenic sites. 
Attempts were made to chemically synthesise regions 
corresponding to these sites and containing the disulphide 
bonds, but this proved too difficult for routine use 
(Atassi et al, 1975). Diglycyl segments, however, 
were found to be ideal replacements for disulphides 
in chemical synthesis experiments. This newly developed 
concept of chemically synthesising a region where 
the constituent amino acids are not generally found 
sequentially linked by peptide bonds in the native 
protein was called 1 surface-simulation synthesis'
(Atassi et al, 1976a).
For antigenic site 2, the initially implicated 
residues from chemical modification experiments are 
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Fig.1a shows the residues (ringed) thought to be important 
for the antigenicity of site 2 of hen egg lysozyme 
following fragmentation work.
Fig.1b shows the synthetic site found to carry the full 
reactivity of site 2.
Fig.1c shows the constituent residues of the native site 2 
of hen egg lysozyme. The distances (in nm) separating the 
constituent residues and the overall dimension of the site 
(in its extended form) are given, together with the 
dimension of the surface - simulation site.
Following synthesis of a variety of peptides of the 
type shown in fig 1(b), the final constituent residues 
of the antigenic site, fig 1(c), were delineated (Lee 
and Atassi, 1976; Atassi, 1978). This was the first 
antigenic determinant shown to comprise of surface 
residues in close proximity by virtue of the folding 
of the polypeptide chain, but which are not sequentially 
linked by peptide bonds. This type of epitope is called 
a discontinuous antigenic determinant (sometimes termed 
topographic).
All three major antigenic sites of lysozyme 
are found to be discontinuous, they each contain 5-6 
residues and are between 2.1-3.0nm in their extended 
dimensions.
1.2.3 The effect of substitutions, and the role of 
conformation on antigenicity
Conformational changes intentionally imposed 
on Hb and Mb by chemical alterations in the haem moity 
(outside the antigenic site) lead in each protein 
to alterations in its antigenic reactivity (Atassi,
1967; Reichlin et al, 1963).
Using cross-reactivity data for many well 
defined protein systems White et al, 1978, showed 
how residues subject to evolutionary substitution in 
proteins exert an influence on antigenicity. This 
may be by directly altering a reactive site, or by 
exerting indirect conformational changes in the
12
determinant (East et al, 1980).
Lysozyme and c<-iactalbumin, 2 highly homologous 
proteins, do not exhibit any immunochemical cross­
reactivity because of conformational differences between 
the two proteins (Habeeb and Atassi, 1971b). However, 
when unfolded by reduction or alkylation, the 2 proteins 
exhibit the expected immunochemical cross-reactivity 
with antisera raised against either unfolded protein 
(Arnon and Maron, 1971).
Lee anA 19 77, showed that nitration of
a tyrosine outside an antigenic site of lysozyme creates 
an electrostatic inductive effect which disrupts the 
reactivity of that site. No detectable conformational 
changes were associated with this modification (Atassi, 
1978) .
In myoglobin, 22% of residues are involved 
in antigenic sites, and yet 80% of substitutions are 
immunologically detectable (Berzofsky et al, 1982). 
Residues as far away as 1.6nm distant from an antigenic 
site have been shown to exert conformational restrictions 
neccessary for antibody binding at the site (Twining 
et al, 1980). If all the residues within 0.7nm of an 
antigenic site were arbitrarily considered to be important 
environmental residues, an additional 56% of Mb residues, 
(giving a total of 78%) would be found to exert effects 
on its antigenicity (Kazimand. P)kassi,1980) .
Thus conformational changes in an antigen 
brought about by chemical modification or evolutionary
13
change have been shown to be of great importance in 
influencing antigenicity. The extent and nature of 
conformational changes has a variable effect on 
antigenicity depending on the protein (Andres ctnA AfcassL, 
1970; Atassi et al, 1972).
1.2.4 Level of antibody responses to regions outside 
the main antigenic sites
Although epitope studies of swMb and hen egg 
lysozyme account for approximately 98% of the antibodies 
raised against these native proteins, there is a low 
level of antibody response (approximately 2%) versus 
other regions (Atassi, 1980; Atassi and Lee, 1978).
Dean and Schechter, 1979, found a subpopulation of 
less than 1% of total anti-Hb antibodies bound to an 
©<129-141 epitope. This could only be detected when 
a large excess of antibody was used.
1.2.5 Summary
This section has discussed the discovery of 
the existence of two types of antigenic site, using 
polyclonal antibodies raised against native proteins. 
Myoglobin contains five major antigenic sites of the 
continuous type, lysozyme has three major antigenic 
sites of the discontinuous type.
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The use of monoclonal antibodies (mAbs) discussed 
in the following section, enables the examination of 
the overall antibody response in finer detail. This 
includes the ability to study minor antibody responses 
contained in serum antibodies, see section 1.2.4.
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1.3 Monoclonal Antibodies
The immune response has evolved to combine
the maximum efficiency of clearing specific foreign
antigens from the host, with the least likelihood of
reacting with self. Dependent on the regulation of
Immune response (Ir) genes and balance of T^/T cell
H b
activity to each possible epitope, a polyclonal serum 
is produced which is a disproportionate mixture of 
a variety of monoclonal antibodies, against the sum 
of the various epitopes of the antigen. The polyclonal 
serum contains monoclonal antibodies of various classes 
and sub-classes, with various affinities to each epitope 
present on the antigen.
The development of hybridoma techniques, to 
select and immortalize individual monoclonal antibody 
secreting cells (Kohler and Milstein, 1975) has allowed 
the dissection of polyclonal serum into its individual 
components. Normal antibody-producing B lymphocytes 
do not grow readily in culture. However, when fused 
with a myeloma cell line (derived from a B-lymphocyte 
malignancy) a hybridoma is produced which secretes 
the antibody of the primed B cell, yet can be grown 
indefinitely in culture.
This permits amplification in vitro of what 
would ordinarily constitute trace antibody responses 
in vivo. By definition a monoclonal antibody preparation 
contains antibodies of only one type and specificity.
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The potential uses of monoclonal antibodies 
in biological systems are immense and they have been 
raised to a diverse list of molecules, see table 1.
Due to their specificity, mAbs are used as 
biological tools and markers in purification, quantitation, 
structure/function studies, and histology, see table 2.
MAbs may also be used for the polysome purification 
of specific mRNAs, for molecular cloning and for 
purification of translated products. In vivo, the use 
of mAbs tagged to cytotoxic agents offers potentially 
exciting selective cancer therapy, or drug targeting 
An example of a target may be the enzyme xanthine oxidase 
for treatment of breast carcinoma (Vora, 1985).
1.3.1 Epitope analysis using monoclonal antibodies
Studies of the antigenic determinants bound 
by monoclonal antibodies have predominantly been 
restricted to those concerning continuous epitopes.
The difficulty of examining discontinuous epitopes has 
been emphasised in section 1.2.2.
Peptide mapping studies using mAbs make wide 
use of the immunoblotting procedure of Towbin et al,
1979, whereby protein fragments are electrophoretically 
transferred from polyacrylamide gels to nitrocellulose 
sheets and the reactive bands probed with antibodies. 
Antigenetically reactive fragments can also be identified 
by their retention on mAb immunoadsorbent columns
17
Examples of the diverse list of antigens to 
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(Duffy and Kurosky, 1982), or by their precipitation 
using antibody. Readily purified fragments may also 
be probed with antibodies in radioimmunoassays and 
enzyme-linked immunosorbent assays (ELISA), to test 
for reactivity.
Two examples of protein studies performed using 
monoclonal antibodies are those of the acetylcholine 
receptor (Ratnam et al, 1986a-)y and hexokinase A (Ureta 
et al, 1986). These will be discussed to illustrate 
some of the uses of mAbs in performing structure/ 
function studies of proteins.
1.3.2 The study of acetylcholine receptor using monoclonal 
antibodies
The nicotinic acetylcholine receptor of Torpedo 
californica is composed of four types of glycoprotein 
subunit in an c*2 j3y£ stoichiometry (Raftery et al, 1980).
The receptor is a cation channel in the membrane and 
is regulated by the neurotransmitter, acetylcholine 
(Neher and Sakman, 1976). Significant homology has been 
shown between the subunits, the amino acid sequences 
of which are known. Structurally all the subunit 
C-termini have been shown to be intracellular (Young 
et al, 1985).
Over 200 anti-AChR mAbs have been raised 
(Criado et al, 1985; Mochly-Rosen and Fuchs, 1981).
A few mAbs have been shown to inhibit receptor function 
noncompetitively (Blatt et al, 1986).
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Monoclonal antibodies have become available 
which bind specifically to the C-terminal decapeptides 
of subunits c*,p and 8 ; the y  subunit has not yet been 
studied (Lindstrom et al, 1984) . Fragments of the subunits 
have been produced by digestion with staphylococcal 
V8 protease, and papain, separated on a discontinuous 
polyacrylamide gel electrophoretic system and 
electroblotted onto diaminophenyl thioether paper 
(Ratnam et al, 1986<x;Souroujon, 1986). Blots have been 
probed with monoclonal antibodies against the carboxy- 
terminal decapeptides of the c*.,^ and 5 subunits. This 
identified the carboxy terminal fragments, and by 
assuming a mean residue weight of 115, fragments were 
assigned to appropriate amino acid sequences. After 
probing the blots with anti-AChR mAbs, it was possible 
to map the binding of these mAbs onto the amino acid 
sequences of the AChR subunits. In this way, the main 
immunogenic region of the native receptor which is 
of pathological importance in the autoimmune disease 
myasthenia gravis has been mapped (Ratnam et al, 1986o-)„ 
Further studies of the AChR using mAbs are 
in three main areas:
a) Using colloidal gold-protein A as a means 
of visualizing mAbs bound to vesicles under electron 
microscopy, information has been obtained on the 
transmembrane orientation of the polypeptide chains 
of the receptor within the membrane (Ratnam et al,
1986b').
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b) Regions of the primary sequence of AChR 
with a direct role in its physiological functioning
can be identified by mapping mAbs that affect the channel 
activity. However, these studies are difficult to 
interpret (Wari and Lindstrom, 1985; Blatt et al, 1986).
c) Mapping the overall antigenic structure
of the receptor will enable the pinpointing of peptide 
sequences that play critical pathogenic roles in the 
autoimmune disease myasthenia gravis (Lindstrom, 1985) .
This work shows how mAbs are used to elucidate 
antigenic epitopes, study the orientation and structure 
of complex proteins and examine structure/function 
relationships.
1.3.3 Hexokinase A
A library of seven mouse mAbs was raised against 
rat brain hexokinase (Finney et al, 1984). Using a 
direct coating ELISA, 3 mAbs were shown to react with 
rat, mouse, guinea pig, cat, dog, sheep, pig, cowf rabbit 
and chicken brain hexokinase, showing wide species 
conservation at these epitopes. The other epitopes 
differed markedly in species distribution, although 
the direct ELISA may not be the best assay to use for 
cross-reactivity studies.
Peptide mapping (after limited tryptic 
digestion) in conjunction with immunoblotting techniques 
employing mAbs, showed the domain structures of the
22
various species' hexokinases to be similar to those 
of rat hexokinase. However, the domain sizes varied 
between the species (Ureta et al, 1986; Wilson and 
Smith, 1985). None of the mAbs affects the enzyme activity, 
which suggested that they bound at sites spatially 
distinct from the active site (Finney et al, 1984).
This work shows how mAbs can be used to study enzymic 
structure/function relationships and to examine epitope 
diversity across species.
1.3.4 Summary
A mAb preparation contains only one antibody, 
representing an individual component of a polyclonal 
serum. A polyclonal antiserum will also contain 
antibodies versus other antigens as well as those 
against the antigen used to immunise the host.
Use of mAbs enables the investigation of the 
individual epitopes present on an antigen with a specific 
probe. Hence, the individual epitopes can be examined 
for their species conservation, or their importance 
in the function of the protein (i.e. enzyme activity).
Due to their specificity, mAbs are far superior to 
antisera for use as immunochemical markers, for affinity 
purification and in immunoassays.
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1.4 Strategies for Predicting Protein Antigenic 
Sites
The question of what an antibody actually 
'sees' when it recognises its antigen has not yet been 
fully answered. The total surface available on the 
antibody for antigen contact is large, about 4 x 5nm 
(Rees and Ae la Paz, 1986). Precisely how much of this 
surface is utilized obviously depends upon the size 
and shape of the antigen. Some antibodies have been 
shown to be capable of binding to single amino acids 
and dipeptides (Geysen, 1985), although the optimal 
epitope size to maximise antibody binding efficiency 
is generally accepted as being between 5-10 residues 
(Amit et al, 1985).
The analysis of which parameters are involved 
in antigen-antibody interactions and the selection 
of optimal sequences to use as synthetic immunogens 
is only readily performed for continuous epitopes, 
leaving discontinuous sites, as yet, largely uncharted.
Experimental analysis of antigenic sites is 
an arduous procedure. Thus, much work is presently 
being performed to try and find a predictive approach 
for locating the sites on a protein which are 
antigenically important. Following correlation studies 
of known protein antigenic structures (found by 
experimental means) with various physical parameters, 
using computer analysis, some predictive methods have 
been suggested. The parameters used include accessibility,
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surface protrusion, hydrophilicity, mobility and 
structurally inherent antigenicity. They are discussed 
in the following sections.
1.4.1 Accessibility
For antibodies to bind a protein antigen in 
solution, antigenic sites should be accessible on the 
surface of the native protein, consistent with the 
work of Atassi, 1984. Molecular surface calculations 
can be performed on a protein of known structure by 
mathematically rolling a solvent water molecule over 
the van der Waal's surface of the protein (Hubbard 
and Ivatt, 1981; Rice et al, 1982).
Exceptions to this requirement for antigenicity 
however have been found. When a mAb isolated from a 
mouse immunized with native swMb was used in a 
competitive ELISA, native swMb failed to compete for 
antibody with swMb bound directly to an ELISA plate.
The mAb did however bind swMb, horse Mb and a synthetic 
peptide by direct ELISA. Clearly this mAb recognises 
a sequential epitope which is only readily accessible 
when myoglobins are adsorbed onto a surface (Geysen, 
1985) .
Studies with monoclonal antibodies directed 
against the ^  2-sut:)un:*-t E .coli trytophan synthase 
have shown that some antibodies bind rapidly to the 
native antigen in solution, while others preferentially
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recognise the antigen only when it has been adsorbed 
onto the surface of ELISA plates (Friguet et al, 1984;
Djavadi-Ohaniance et al, 1984).
Thus antibodies can be induced, during antigen 
presentation, to epitopes which are inaccessible to 
antibody when the native antigen is in solution.
1.4.2 Protrusion Index
This method is an extension of accessibility, 
and takes account of the extent to which a residue 
protrudes out into the solvent. To evaluate the protrusion 
of a residue, Thornton et al, 1985, calculated 
equimomental ellipsoids' to fit proteins of known 
crystallographic structure. A 100% ellipsoid contained 
100% of the atoms of the protein within it. A 90% 
ellipsoid, however, included 90% of the residues, with 
10% protruding outside it. Any residue protruding beyond 
a 90% ellipsoid was assigned a 'protrusion index' (PI) 
of 9, those outsidean 80% ellipsoid assigned PI=8 
etc.. Following assignment of PI values to all the 
amino acids of myoglobin, lysozyme and myohaemerythrin, 
plots were drawn of PI value versus residue number.
A good correlation was found between residue PI maxima, 
and the locations of amino acids involved in known 
antigenic sites.
For future use where only the primary sequence 
is available, Thornton et al have averaged the PI
2 6
values of the amino acids found from known structures 
to give predicted protrusion values for each amino 
acid.
1.4.3 Hydrophilicity
For water soluble globular proteins to be 
stable in an aqueous environment, they fold into a 
structure which tends to bury hydrophobic residues 
in their interior, and to expose their mostly hydrophilic 
ones on the surface (Berzofsky, 1985)
In an attempt to find a method to predict 
the location of antigen sites from primary sequence 
data, Hopp and Woods (1981) suggested that the most 
hydrophilic segments of a sequence would correlate 
well with antigenicity, because these segments are 
most likely to be on the external surface of a protein. 
Each amino acid was assigned a numerical value 
(hydrophilicity index) based on the polarity of its 
side chain, the data largely coming from the solvent 
parameters of Levitt, 1976. Repetitively averaging 
these values for overlapping sets of 6 residues along 
the chain and plotting them versus the residue number 
of the leading residue gives a hydrophilicity profile, 
where a positive value indicates an above average 
hydrophilicity. Using 12 proteins for which antigenic 
sites were known, they found that the segment of 
greatest hydrophilicity for the entire protein was
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invariably in one of the known antigenic sites. This 
approach was then applied to the sequence of the 
hepatitis B surface antigen in order to- identify potential 
antigenic sites. Following chemical synthesis of the 
most hydrophilic peptide predicted, it was experimentally 
shown that this corresponded to a major antigenic 
determinant of that virus (Hopp and Woods, 1981; Hopp 
and Woods, 1983). However, the secondary peaks of 
hydrophilicity do not always correlate well with known 
antigenic sites. For example, only 2 of the 5 main 
antigenic sites of myoglobin coincide with hydrophilicity 
maxima, and some hydrophilicity maxima are not antigenic 
(Atassi, 1984). For Influenza virus haemagglutinin, 
a strongly immunogenic region has been reported which 
is so hydrophobic that the corresponding synthetic 
peptide is insoluble in aqueous solvents (Atassi and 
Webster, 1983).
1.4.4 Mobility
Protein molecules in solution do not remain 
in one set conformation, but due to internal dynamics, 
parts of the molecule are continually making small 
conformational changes (Artymuik, 1979; Pain, 1983).
Most of the detailed information relating to protein 
conformational changes have been obtained from 
highly refined x-ray crystallographic data (Ringe and 
Petsko, 1985). Present refinements to this technique
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not only give precise atomic coordinates, but also atomic 
temperature factors (B values) (Frauenfelder et al,
1979). The temperature factor represents the mean-square 
displacement of each atom,and when plotted against 
residue number gives a graphic image of the degree of 
mobility existing along the polypeptide chain (Williams 
and Moore, 1985). Useful information on mobility can 
also be obtained from nuclear magnetic resonance studies 
(Moore and Williams, 1980).
Information from these techniques is not readily 
available at present for many proteins, and mobility 
predictions are certainly not applicable to cases 
where only the primary sequence is known (Berzofsky,
1985).
Two different approaches have been used to 
study the relationship between antigenicity and mobility, 
the binding of antibodies to peptides and the binding 
of antibodies to proteins. Antibodies raised against 
proteins are made against a more conformationally 
restricted molecule, whereas antibodies raised against 
peptides have a much less conformationally restricted 
epitope.
Peptides in solution exist in a large number 
of conformations in a dynamic equilibrium (Kaiser and 
Kezdy, 1983). Considering this, a suprisingly high 
proportion of mAbs raised against peptides react with 
the intact protein (over 60% in one study of four 
proteins) (Niman et al, 1983).
Tainer et al, 1984, raised polyclonal
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antibodies to 12 peptides, each of between 10-15 
residues, covering 70% of the exposed molecular surface area 
of myohaemerythrin as defined by X-ray crystallography.
A very good correlation was found between mobility of 
segments in the native protein and the ability of 
antibodies to bind to these sites on the native protein 
in solution. This correlation was shown to be with the 
mobility of exposed surface regions, and not just due 
to surface exposure. However, highly exposed amino acids 
do tend to be less hydrophobic and due to their external, 
relatively unconstrained position are more highly mobile 
than internal residues (Levitt, 1983).
Thus, atomic mobility of a segment of the 
native protein is a critical factor in determining the 
ability of antibodies against short peptides corresponding 
to that segment to bind to the native protein.
A second approach to examine the mobility 
of antigenic sites was to use antisera against the 
native protein. The tobacco mosaic virus protein (TMVP) 
was shown to have 7 continuous antigenic determinants 
as identified using tryptic peptides (Milton and Van 
Regenmortel, 1979; Altschuh et al, 1983). When the 
positions of these epitopes were superimposed on a plot 
of temperature factors of main chain TMVP atoms, it 
was found that all seven antigenic regions corresponded 
to mobility peaks (Westhof et al, 1984). This correlation 
was better than that between antigenicity and either 
hydrophilicity or accessibility. Similarly, a good 
correlation was found between reported continuous
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antigenic sites of myoglobin and segmental mobility.
These same investigators have concluded that the entire 
surface of the TMVP is antigenic, although composed 
primarily of discontinuous epitopes. They suggested 
that no single criterion can be used to distinguish 
generally nonantigenic from antigenic regions (Al 
Moudallal et al, 1985).
One explanation for the apparent correlation 
found between antibody binding to continuous epitopes, 
and mobility is an induced fit hypothesis (Tainer et 
al, 1984; Marx, 1984). In the induced fit model, an 
initial weak binding is stabilized by a conformational 
change in the antigen induced by the antibody. In an 
allosteric model (Berzofsky, 1985), an unfavourable 
conformational equilibrium is 'pulled' towards the 
complementary form by trapping of the complementary 
molecules in a tight complex by the antibody.1 £ ‘the antibody 
also undergoes a conformational change, a further model 
can be envisaged (Edmundson et al, 1984).
Geysen, 1985, has suggested how a thermodynamic 
analysis can be used to explain the interaction between 
antibody and antigen, allowing for the possibility of 
conformational changes occurring in both the antibody 
and the antigen.
1.4.5 Composite Surface Profile
No single parameter has so far been shown
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able to predict all the antigenic sites on any protein. 
Recently a new set of hydrophilicity indices has been 
derived from the retention times of twenty model 
synthetic peptides in high performance liquid 
chromatography (HPLC) (Parker et al, 1986). This group 
has produced a composite predictive method consisting 
of HPLC hydrophilicity indices, accessibility (Janin, 
1979) and flexibility B-values (Karplus and Schulz,
1985) . This composite profile was shown to correlate 
well with the known antigenic sites for several proteins 
including myoglobin, lysozyme, cytochrome c and influenza 
HA1 (Parker et a l , 1986)
1.4.6 Structurally Inherent Antigenic Sites
Initially it was thought that immunogenic 
sites on a protein antigen differ in sequence from their 
counterpart in the host (Urbanski and Margoliash, 1977). 
However, it has been found that rabbit or mouse antisera 
against bovine or human serum albumin exhibit 
autoreactivity against the animal's own albumin (Atassi 
et al, 1982). Also rabbits injected with rabbit myoglobin 
can produce antibodies to it, although use of Freund's 
complete adjuvant (FCA) is neccessary for this to occur. 
Therefore, a protein need not be foreign to be 
antigenic. It may be that FCA assists in overcoming 
tolerance to self-proteins through the by-passing of 
T cell suppression.
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The antigenicity of proteins is conferred on 
certain surface regions by virtue of the three- 
dimensional locations of these sites. Therefore it would 
follow that antigenic sites of conformationally related 
proteins are likely to have similar molecular locations. 
Using t.his concept it has been possible to predict by 
extrapolation of the three-dimensional locations of 
the antigenic sites of swMb, many of the sites of human 
Hb (Karzim and Atassi, 1982) and also those of soybean 
leghaemoglobin, a distantly related haem protein 
(Hurrell et al, 1978).
Recently, a computer search has been performed 
to identify a set of peptide seguences, containing at 
least six amino acids that occur in unrelated proteins 
(Wilson et al, 1985). Antibodies are to be raised against 
these peptides and tested for cross reactivity against 
them in their different conformations in the various 
proteins. In this way it will be possible to investigate 
further the roles of conformation and mobility in 
antibody binding.
In summary, accessibility, protrusion, 
hydrophilicity, mobility and inherent conformations 
may all play a vital role in antigenicity. However, 
a much larger database of experimental results is needed 
before the relative importance of each can be defined.
Citrate synthase is a very well characterised 
protein, as discussed in the following section, and 
sufficient information is available to apply all the 
predictive methods, previously discussed, to it.
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2.1 The Citric Acid Cycle
The citric acid cycle (fig. 2) operates in 
most living organisms and has a dual role:
a) During the degradation of carbohydrates, fats and 
amino acids it provides reducing equivalents to the 
electron-transport chain, for energy production in the 
form of ATP.
b) It supplies precursors used in gluconeogenesis, 
lipogenesis, ketogenesis and amino acid biosynthesis.
Even in facultative anaerobes, which lack 
2-oxogluterate dehydrogenase during anaerobic growth, 
the enzymes of the cycle are able to operate as two
arms (citrate > 2-oxoglutarate, oxaloacetate >
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Fig.2 The Citric Acid Cycle. The enzymes are :1-citrate 
synthase, 2-aconitase, 3-isocitrate dehydrogenase,
4- -oxoglutarate dehydrogenase, 5-succinate thiokinase, 
6-succinate dehydrogenase, 7-fumarase, 8-malate dehydrogenase
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2.2 Citrate Synthase
Citrate synthase (citrate oxaloacetate-lyase 
(CoA acetylating); EC4.1.3.7) catalyses the condensation 
of oxaloacetate and acetyl CoA (Lynen and Reichert,
1951) in the following reaction,
2- 3-
Acetyl-CoA + oxaloacetate + 1^0 s citrate + CoA
+
+ H
Due to its key position in the citric acid 
cycle, citrate synthase has been extensively studied 
and has been shown to play an important regulatory role 
in a cell's metabolism (Beeckmans and Kanarek, 1984; 
Weitzman, 1981? Randle, 1970 and Weitzman and Danson, 
1976) .
In eukaryotes the citric acid cycle enzymes 
are exclusively mitochondrial, with the exception of 
germinating plant seeds where citrate synthase, together 
with enzymes of the glyoxylate shunt, are also found 
in glyoxysomes (Tolbert, 1981). Citrate synthase is 
loosely attached to the inner mitochondrial membrane 
of eukaryotes (Dsouza and Srere, 1983) and is thought 
to be associated with the cell membrane of bacteria 
(Mitchell, 1963). A close association with other enzymes; 
malate dehydrogenase and fumarase (Beeckmans and Kanarek, 
1981), pyruvate dehydrogenase (Sumegi et al, 1980), 
and aspartate amino-transferase (Fahien and Kmiotek,' 
1983), has also become apparent for citrate synthase. 
Recent work by Barnes and Weitzman, 1986, has shown 
by gentle disruption of cells followed by gel filtration
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and sucrose density gradient centrifugation, that five 
sequential enzymes of the citric acid cycle; fumarase, 
malate dehydrogenase, citrate synthase, aconitase and 
isocitrate dehydrogenase specifically associate into 
a cluster.
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2.3 Species dependent properties of citrate synthase
Citrate synthase possesses a diversity of 
subunit structure, catalytic activity and regulation 
which shows a strong correlation with the taxonomic 
status of the source organism (Weitzman, 1981;
Weitzman and Danson, 1976). A summary of these 
relationships is shown in table 3.
Studies of eukaryotic, and Gram positive 
bacterial citrate synthases have shown them to be 
inhibited by ATP (Jangaard et al, 196 8; Hathaway and 
Atkinson, 1965”) . This inhibition has been shown to be 
isosteric, ATP competing with the substrate acetyl-CoA 
at the active site (Harford and Weitzman, 1975).
Gram negative bacterial citrate synthases 
have proved insensitive to ATP (Weitzman, 1966), 
however they are inhibited allosterically by NADH.
Within this group, the enzymes of obligate aerobes can 
be reactivated by AMP, while those of facultative 
anaerobes cannot (Weitzman, 1981). In Gram positive 
bacteria and eukaryotes, citrate synthases are generally 
much less inhibited by NADH, than those of the gram 
negative bacteria (Weitzman and Danson, 1976).
Inhibition of citrate synthase by 2-oxoglutarate 
was shown to be allosteric and only occurred in 
facultatively anaerobic Gram negative bacteria (Weitzman 
and Dunmore, 1969).
Investigation of the molecular sizes of the 
citrate synthases of Gram negative bacteria has shown

















































270,000 270,000 90,000 110,000 85,000 90,000Molecular
weight
Type large large smal 1 smal 1 smal 1 - smal 1
Subunit hexamer hexamer dimer - dimer - dimer
composition
INHIBITION
NADH allosteric allosteric none none none yes v. little
(reactivated (AMP has no (isosteric
by AMP) effect)
2-oxo- none allosteric none none none yes none
glutarate
ATP none none isosteric weak yes yes isosteric
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them to be 'large', existing as hexamers with approximate 
molecular weights of 270,000 (Tong and Duckworth, 1975; 
Robinson et al, 1983a.). In contrast, Gram positive bacteria 
and eukaryotic organisms possess 'small' citrate 
synthases, which are dimers with total molecular weights 
of approximately 90,000 (Weitzman, 1981; Robinson et 
al, 1983b). However, it should be noted that the subunit 
sizes in both the 'large' and 'small' type enzymes are 
similar.
Archaebacteria consisting of halophiles, 
thermoacidophiles and methanogens are proposed to 
constitute a third evolutionary line of descent (Woese, 
1981). Of those studied to date, the citrate synthases 
of the thermoacidophiles have been shown to be dimers 
of total molecular weight 85,000. They are sensitive 
to inhibition by ATP (Danson et al, 1985). Halophiles 
also have the small type of citrate synthase and are 
inhibited only weakly by ATP. Citrate synthase from 
the methanogen Methanosarcina barkeri was unusually 
inhibited by ATP, NADH and 2-oxoglutarate; however 
the enzyme is present in very low amounts and therefore 
its molecular size has not yet been determined (Danson 
et al, 1985) .
In summary, allosteric regulation is seen 
only in 'large' citrate synthases, the regulation 
of the 'small' enzymes being isosteric.
A complementary approach has been used to 
study the structure/function relationships of citrate 
synthases. This was achieved using the facultative
41
anaerobe Escherichia coli. The 'wild type' of this 
organism produces a 'large' citrate synthase, of 
molecular weight 270,000, which is sensitive to 
allosteric inhibition by both NADH and 2-oxoglutarate 
(Weitzman and Danson, 1976). From mutagenesis work, 
a mutant of E .coli was produced, whose citrate synthase 
was small, of molecular weight 100,000, and was 
insensitive to inhibition by either NADH or 
2-oxpglutarate (Danson et al, 1979). The apparently 
minor genetic alterations involved in this conversion 
emphasises the strong relationship between the structure 
and function of citrate synthase, and may mimic natural 
mutations which have occurred to produce the existing 
diversity of citrate synthases.
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2.4 Primary sequence data for citrate synthase from 
pig heart, E.coli and yeast
Amino acid sequencing performed on fragments 
of pig heart citrate synthase (PHCS) produced by 
proteolytic (Bloxham et al, 1980) and chemical means, 
has provided the complete amino acid sequence of this 
enzyme (Bloxham et a l , 1981; Bloxham et al, 1982), 
see fig. 3.
Primary sequence data for citrate synthase 
from E .coli came first from sequencing the gene (Ner 
et al, 1983). Amino acid sequencing performed on 
fragments produced by proteolytic and chemical digests 
of E .coli citrate synthase have since confirmed the 
majority of this sequence.
The nucleotide sequence of citrate synthase 
from yeast has also been determined by Suissa et al,
1984. The amino acid sequence, derived from the 
nucleotide sequence shows that this citrate synthase 
has a strongly basic amino-terminal region, fig. 3.
It has been proposed that this amino-terminal
region is removed during translocation of the precursor
into mitochondria.
From figure 3, it can be seen that a substantial 
degree of sequence homology exists between the citrate 
synthases of pig heart and yeast (Garforth, 1986).
Citrate synthase from E .coli does show regions of 
homology with both the citrate synthases from pig 
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Fig. 3,
Comparison between the amino acid sequences of citrate 
synthase from pig heart (PCS),yeast (YCS) and E.coli (ECS). 
The sequences are aligned to maximise homologies.Regions 
of homology are boxed.Adapted from Suissa et al 1984. 
Residues are numbered according to the sequence of PHCS.
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between the pig heart and yeast enzymes. Residues 
shown to be essential for catalysis in the PHCS are 
highly homologous in both the yeast and E .coli enzymes. 
These include His235, His238, His274, His320, Arg329 
and Asp375 (Suissa et al, 1984).
The availability of primary sequence data 
makes citrate synthase an ideal enzyme on which to 
perform epitope mapping studies. The relevant limited 
proteolysis and chemical fragmentation work performed 
during the sequencing and verification of the primary 
sequence of PHCS is discussed further in section 
6.0.
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2.5 Physical Structure of Citrate Synthase
An extensive crystallographic study has been 
performed on pig heart citrate synthase and minor work 
on chicken citrate synthase (Wiegand et al 1979;
Remington et al, 1982). For the pig heart enzyme, the 
conformation has been shown to contain 40 helices per 
dimer, packing tightly to form a globular molecule.
Each monomer is divided structurally into two domains, 
see figure 4. The larger domain contains residues 1-274 
(helices A to M) and residues 381-437 (helices S and 
T), while the smaller domain has residues 275-380 
(helices N to R). The subunits are extensively 
interdigitated, with amino acid residues from one subunit 
contributing to the binding of citrate and CoA to the 
other subunit.
Kinetic studies, by Johansson and Pettersson 
(1977) have indicated that the interaction of citrate 
synthase with its substrates follows an ordered 
mechanism. Initial binding of oxaloacetate increases 
the ability of acetyl-CoA to bind to the enzyme.
The structure of the enzyme has been described 
in three states (Remington et al, 1982; Wiegand et 
al, 1984). It has been proposed that binding of 
oxaloacetate to the 'open' form of the enzyme induces 
a 'closed' form in which the binding site for coenzyme 
A is developed. A further 'closed' form is found which 
has bound citrate. The conformational changes in 
response to changes in the state of ligation have been
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PIG HEART CITRATE SYNTHASE
(monomeric form)
A 5 - 29 K 221 - 236
B 37 - 43 L 242 - 255
C 70 - 78 M 257 - 271
D 88 - 99 N 274 - 291
E 103 - 118 0 297 - 312
F 121 - 131 P 327 - 341
G 136 - 152 Q 344 - 365
H 153 - 161 R 373 - 386
I 163 - 195 S 390 - 416
J 208 - 218 T 426 - 433
Fig.4 Schematic representation of the structure 
of PHCS
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studied by another group of workers (Lesk o-nA ChobW’icL, 
Chothia and Lesk, 1985). The conformational forms of 
the enzyme were explained in terms of helix movements, 
the most pronounced occurring of helix 0 on the outside 
of the small domain. This is in agreement with the 
proposal of Wiegand et al 1984, who suggested that 
the small domain is more flexible than the large 
domain.
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2.6 Immunochemical Study of Citrate Synthase
Moriyama and Srere, 1971, showed by Ouchterlony 
double diffusion that an antiserum raised against rat 
heart citrate synthase was able to cross-react with 
rat liver, kidney, brain and spleen enzymes. However, 
no reaction was seen with PHCS, or CS from moth muscle, 
Azotobacter, or mango. Further experiments using this 
antiserum for enzyme precipitation and in double 
immunodiffusion experiments suggested that the rat 
kidney C S , heart CS and brain CS are immunologically 
identical (Matsuoka ctncX Srere,'^ 73), However the 
insensitivity of the double immunodiffusion method 
must be emphasised in drawing such conclusions.
Other antisera raised against yeast CS have 
proved useful for precipitation of the translation 
products of mRNAs, to identify which mRNAs could be 
used to produce cDNA sequences coding for CS (Suissa 
et al, 1984; Alam et al, 1982).
In an attempt to discover which domain of 
PHCS had the greater antigenicity double diffusion 
assays and immunoprecipitation experiments were 
performed on various proteolytic digest mixtures of 
PHCS (Bloxham et al, 1980). The relative impurities 
of the fragments used in this assay, however, may 
overrule the conclusion that the small domain is the 
primary antigenic domain.
The ability to use rabbit antibodies raised 
against PHCS in an immunochemical investigation of 
interspecies diversity was shown by Pullen et al,
1985. In a competition enzyme-linked immunosorbent
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assay, where plates were coated with pigeon breast 
CS, they showed the order of competition to be 
PHCS > pigeon breast CS > Bacillus megaterium CS >
E .coli CS. The same order of reactivity was shown in 
enzyme inhibition experiments. In this experiment, 
however, the antibodies appeared able to activate the 
citrate synthase from E.coli. Finally, cross-reactivity 
was studied by examining the ability of the rabbit 
anti-PHCS immunoglobulins to precipitate out enzyme 
activity from solution using Staphylococcus aureus 
protein A as a cross-linking agent. In this assay both 
the PHCS and E .coli CS tested were shown to be 
precipitated. This work shows conclusively that citrate 
synthases from pig heart, pigeon breast, B .megaterium 
and E .coli share common antigenic determinants.
This work confirms the feasibility of using 
immunochemical methods to investigate the structural 
diversity of citrate synthase and provides the basis 
for the application of monoclonal antibodies.
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Aims of this Study
The work described in this thesis is
designed:
1. to raise, using different screening methods, 
a library of mAbs specific for PHCS
2. to investigate the potential of various immunochemical 
screening methods for future use
3. to characterise the binding of mAbs to PHCS using 
epitope analysis of fragments of PHCS
4. to compare the experimentally determined epitopes
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MATERIALS
3.1 Cells and cell culture material
The HAT sensitive mouse myeloma X63-Ag8.653 
and the human epithelial cell line HEp-2 were obtained 
from Flow Laboratories, Scotland.
Sterile media, supplements and plasticware 
were obtained from Nunc Gibco, Flow Laboratories 
and Sterilin.
All PBS used for cell culture was prepared 
from tablets obtained from Flow Laboratories, PBS 
Dulbeccos formula (modified) calcium and magnesium 
free. The trypsin used was Type XI from bovine 
pancreas, salt free, Sigma T-1005.
Complete RPMI contained RPMI 1640, 4mM
glutamine, 50|jM 2-mercaptoethanol (Sigma) , 10% (v/v)
-1
'myoclone' foetal calf serum (FCS) and 50jjgml 
kanamycin. Tylocine at 60|jgml  ^ was sometimes used in 
place of kanamycin.
Complete BME contained BME (modified) with 
Earle's salts, 4mM glutamine, 10% (v/v) FCS or newborn 
calf serum (NCS) and 50pgml  ^ kanamycin.
Freezing medium contained 50% (v/v) myoclone 
FCS, 20% (v/v) DMSO, 30% (v/v) complete medium and 
was stored at -20°C.
45% Polyethylene glycol (PEG) solution 
was prepared by autoclaving 4.5g PEG 4000 (GK), 
from Merck, with 5ml PBS. 0.5ml of dimethyl sulphoxide
55
(DMSO) was added after cooling and it was found 
that the solution could be stored for up to 1 month 
at room temperature.
3.2 General reagents and solutions
All chemicals used came from Sigma or BDH, 
and were of Analar or equivalent grade except palmitoyl 
CoA, which was a gift from Dr. T. Else. All enzymes 
were purchased from Sigma, or Boehringer Mannheim. 
Subtilisin BPN', protease type VII was Sigma P-5255, 
chymotrypsin type II from bovine pancreas was Sigma 
C-4129, and trypsin type III-S from bovine pancreas 
was Sigma T-2395. Immunochemical reagents were from 
Sigma, unless stated. Chromatography media were 
obtained from Pharmacia.
The solutions were prepared using glass 
distilled water. Buffers were made as described 





3.3 Maintenance of cell lines
Mouse myelomas (X63-Ag8.653) and established 
hybridomas, were grown at 37°C in complete RPMI 
in an atmosphere of 3.5% CO2 in air with a relative 
humidity of 95%. Under these conditions the cell 
lines had doubling times of 18-24h, and were maintained 
in log phase growth. The HAT sensitivity of myelomas 
was maintained by periodic inclusion of 0.13mM 
8-azaguanine in the culture medium.
The human epithelial cell line HEp-2 was 
grown at 37°C, in monolayer culture in complete 
B.M.E., in an atmosphere of 5% CC^ in air with 
a relative humidity of 95%. When cells had grown 
to confluency, they were harvested by trypsinisation 
and new cultures initiated at a split ratio of 
1:40.
For trypsinisation, cells were washed
with PBS and incubated for 1 min at 37°C with trypsin
2
(lml of 0.05% trypsin in PBS/5cm area). The trypsin 
was decanted and the flask closed and incubated 
at 37°C for 15 min. Cells were resuspended in medium 
prior to sub-culturing.
3.4 Cell counting
For a total cell count, equal volumes 
of cell suspension and Turk's solution (10% (w/v)
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gentian violet, 3% (v/v) glacial acetic acid) were 
mixed and incubated for 5 min at room temperature.
All cells are stained by this method.
For a viability count, equal volumes of 
cell suspension and nigrosine (0.2% (w/v) in PBS) 
were mixed and incubated for 5 min at room temperature. 
Only dead cells are stained by this method.
In both cases, cell counting was performed 
using a haemocytometer with improved Neubaeur ruling.
3.5 Cryopreservation of cells
6Up to 5 x 10 cells were pelleted by 
centrifugation at 200g for 5 min, and resuspended 
in 0.5ml complete medium. The suspension was 
transferred to a 2ml cryopreservation tube, and 
cooled on ice for 15 min, prior to the addition 
of an equal volume of cold freezing medium. Ampoules 
were placed in the vapour phase of liquid nitrogen 
to freeze at a rate of -1°C per min, then stored 
in liquid phase nitrogen until required. Frozen 
cells were recovered by rapid thawing to 37°C, 
followed by washing with PBS and resuspension in 
complete medium.
3.6 Preparation of mouse peritoneal feeder cells, 
for hybridoma growth
Adult BALB/c mice were killed by cervical 
dislocation and were then washed in 70% ethanol.
The abdominal skin was removed and 5ml of sterile
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PBS was injected peritoneally through a 20G needle.
After gentle massage of the abdomen, the peritoneal 
cavity was cut open just enough to allow the removal 
of fluid using a pasteur pipette.
The cells were irradiated with 2000 rads 
of -radiation from a cobalt source, and pelleted 
by centrifugation for 5 min at 200g. Following 
resuspension in complete medium, or HAT medium, 
a total cell count was performed.
Feeder cells were used to a final concentration
5
of 1 x 10 cells/ml, whenever a new 4 well or 
96 well tray was used for cloning or cell transfer. 
Feeder cells were also included in flasks when 
a low cell density culture was to be accelerated 
into rapid cell growth.
3.7 Isolation of immune spleen cells
Primed adult BALB/c mice were boosted, 
then killed 4 days later, and their spleens removed 
aseptically. Spleen cells were perfused with 10ml 
of PBS, in a 90mm petri dish. Each spleen yielded
g
approximately 1 x 10 cells.
3.8 Fusions
7
Myeloma cells (1 x 10 ), with a minimum 
viability of 90%, were transferred to a 50ml, sterile, 
siliconised glass centrifuge tube. Spleen cells
0
(1 x 10 ) were transferred to the same tube, care
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being taken to exclude any pieces of *spleen sack.
Cells were pelleted by centrifugation for 5-10 min 
at 200g, and the supernatant was carefully discarded. 
After loosening the pellet, 1ml of PEG solution 
was added dropwise to the pellet with continuous 
agitation. The tube was incubated in a 3 7°C water bath, 
with continuous shaking for 90s, after which the 
following additions of PBS were made: 1ml over 
the first 30s, 3ml over the next 30s, and 16ml 
over the next minute. A further 3-5 min incubation 
at 37°C preceded the cells being pelleted by 
centrifugation and resuspended in HAT medium.
One fusion, as above, would be plated 
out into five 96 well microtitre trays. Alternatively, 
the cells were resuspended in complete medium, 
grown in culture for 24 h, and frozen down into 
5 cryotubes.
For the first 3 weeks of growth after 
fusion, cells were grown in HAT medium, changed 
at least twice. Prior to transfer to complete medium, 
cells were grown for 3 weeks in HT medium which 
was changed at least twice to overcome the toxicity 
of aminopterin alone in the medium.
Cells were screened for the presence of 
anti-PHCS antibodies when they were half confluent 
in the 96 well dishes, approximately 2-3 weeks 
after fusion, or after cloning.
6 0
3 . 9 Cloning of hybrids
Hybrids were cloned by single cell transfer 
(Gagnon and Raymond, 1985) using a micromanipulator 
and microscope. Cells were suspended in 2ml medium 
in a 50mm petri dish, to a concentration at which 
only 1-2 cells were visible under the high power 
lens (magnification of 200 x) of an inverted phase
microscope. For each manouvre, a single cell was
sucked up into a medium reservoir contained in 
a drawn out Pasteur pipette using the micromanipulator 
and transferred to one well of a 96 well tray,
pre-seeded with feeder cells.
3.10 Production of ascitic fluid
Adult BALB/c mice were primed by
introperitoneal injection of 0.5ml pristane
(2, 6, 10, 14-tetramethylpentadecane). Hybrid cells 
5(3 x 10 in PBS) were injected intraperitoneally 
7-14 days after pristane priming. When visible 
growth was observed, 1-3 weeks later, the peritoneal 
cavity was drained every two days for 1 week until 
sacrificing (Brodeur et al, 1984).
3.11 Preparation of HEp-2 slides
Five sterile multitest slides were placed 
in the bottom of a square 120mm sterile petri dish 
and covered with 20ml of complete B^:M.E.. HEp-2 
cells (20ml at a concentration of 5 x 10^ cells ml”-*-
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in complete B.M.E.) were dispersed into the petri dish 
and incubated at 37°C, until cells were approximately 
half confluent on the slides.
Slides were transferred into a Coplin jar, 
and washed twice for 10 min in PBS. Cells were fixed 
by incubating slides for 1 min in ice cold acetone 
followed by 5 min in a further change of ice cold 
acetone. Slides were then allowed to dry in air.
Fixed slides were stored desiccated at -20°C until 
required.
3.12 Immunofluorescence staining of fixed HEp-2 
slides
The method used was adapted from Johnstone 
and Thorpe (1982).
Prior to use, slides were washed twice 
for 10 min with PBS. Blocking was performed by washing 
twice in 20 min with either normal goat serum diluted 
1/10 with 1% casein in PBS, or 1% casein in PBS.
Excess fluid was removed by using a cotton-tipped 
applicator to dry between all wells.
Monoclonal antibodies to be tested were
-1
used at a concentration of lOOngml , and sera were 
used at a 1/40 dilution in PBS. 30|j 1 of diluted 
test sample were applied to each well of a fixed 
multitest slide, which was then incubated at 37°C 
for 30 min. Slides were then washed in three changes 
of PBS, each for 5 min, and again dried between 
wells using a cotton applicator. To each well, 20m1
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of polyvalent goat anti-mouse immunoglobulin-FITC 
conjugate (Sigma), diluted 1:40 in PBS, were added. 
Slides were incubated in a dark humidified chamber 
for 30 min at room temperature, and again washed 
three times in PBS. Finally, to diminish background 
fluorescence, slides were counterstained with 0.01% 
Evan's blue dye, for 5 min.
The slides were mounted by adding 5n1 of 
mounting fluid to each well, and covering with a 
24 x 62mm cover slip. Mounting fluid was 0.1% para- 
phenylenediamine, 10% glycerol adjusted to pH8.0 
with 0.2M bicarbonate buffer pH9.0, and was stored 
at -20°C.
Following examination under a Zeiss 
microscope D-7082 fitted with a UV microscope 
illuminator-100, slides were stored at -20°C.
Antibody Preparation
3.13 Immunisation procedures
(a) Mice: Adult BALB/c mice were injected 
with 200pl of immunogen (50pg PHCS, 100|Jl Freund's 
complete adjuvant (FCA) , made up to 200|j 1 with azide 
free PBS), intraperitoneally, or subcutaneously. 
Booster injections of 200p1 immunogen (50pg PHCS
in 200pl azide free PBS) were given intraperitoneally 
at intervals of 7 days or greater.
(b) Rabbits: Intramuscular injections of
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0.5ml immunogen (200|jg protein in 50% FCA, 50% azide 
free PBS) were given in the hind limbs. Booster 
injections, 0.5ml, of 200pg protein in azide free 
PBS were given at intervals of 10 days or greater.
3.14 Preparation of sera
(a) Mice: Immunized mice, 7 days after 
an antigen boost, were either tail bled (for 20|j 1 
blood), or exsanguinated by cardiac puncture (for 
up to 1ml blood).
(b) Rabbits: Immunized rabbits, 9-10 days 
after an antigen boost, were ear bled for 10ml blood.
Blood was clotted for lh at 37°C, and clots 
removed by centrifugation (in a bench MSE centrifuge) 
at 3,000rpm for 20 min.
Serum was stored at -20°C, either aliquotted, 
or in 50% glycerol.
3.15 Immunoglobulin purification from sera
To rabbit serum, or mouse serum, saturated 
ammonium sulphate solution was added to give a 50% 
saturated solution. Following a 30 min incubation 
at 4°C, with periodic stirring, the precipitate 
was collected by centrifugation at 5,000g for 20 
min. The pellet was redissolved in water, and further 
saturated ammonium sulphate solution added to give 
a 50% saturated solution. Following incubation and 
centrifugation, as before, the pellet was redissolved 
in a minimal volume of 30mM phosphate buffer pH8.0,
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and dialysed against this buffer at 4°C.
Further purification was performed using 
ion-exchange chromatography. DEAE-cellulose (lg 
wet weight for every ml serum) was packed into a 
column (1.8cm diameter) following equilibration 
with 30mM phosphate buffer, pH8.0. The dialysed 
crude immunoglobulin preparation was loaded onto 
the column and eluted with 30mM phosphate buffer, 
pH8.0, at a flow rate of 25mlh Fractions were 
collected until all the protein (immunoglobulin) 
fraction was eluted. Aliquots were stored at -20°C.
Columns were washed with 0.5M NaCl, and 
reequilibrated for further use in 30mM phosphate 
buffer, pH8.0.
3.16 Monoclonal antibody production from ascitic 
fluid
Freshly collected ascitic fluid was clotted 
for lh at 37°C, and clots removed by centrifugation 
(in a bench MSE centrifuge) at 3,000rpm for 20 min. 
Monoclonal antibodies were purified by ammonium 
sulphate precipitation as described in section 3.13. 
The pellet was dissolved in a minimum volume of 
PBS and dialysed against this buffer at 4°C. MAb 
preparations were stored at -20°C, in 50% glycerol.
Further purification was performed using 
affinity chromatography on immobilized Protein A 
by the method of Johnstone and Thorpe, 1982. Protein 
A coupled to Sepharose CL-4B (Pharmacia), at a
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concentration of 2mg protein per ml of gel, was 
packed into the column. Prior to use the column 
was washed stepwise with 0.1M sodium phosphate buffer, 
pH8.0, 0.1M citric acid and 0.1M sodium phosphate 
buffer, pH8.0.
The pellet collected following ammonium
sulphate precipitation of crude ascitic fluid was
dissolved in 0.1M sodium phosphate buffer, pH8.0,
and dialysed against this same buffer. The dialysate
-1
was loaded onto the column at approximately 2mlh ,
(the equivalent of 1ml ascitic fluid was loaded 
per 2ml of coupled Sepharose). The absorbance of 
the eluant was monitored at 280nm, and 2ml fractions 
were collected. The column was extensively washed 
with 0.1M phosphate, pH8.0. Elution was performed 
batchwise with; 0.1M sodium citrate, pH6.0, to obtain 
IgGl, 0.1M sodium citrate, pH4.5, to obtain IgG2a, 
and 0.1M sodium citrate, pH3.5, to obtain IgG2b.
Protein containing fractions were dialysed against 
PBS, and pure mAbs were stored at -20°C in 50% 
glycerol.
Finally, the column was washed with 0.1M 
citric acid and reequilibrated in 0.1M sodium phosphate, 
pH8.0.
3.17 Protein determination
Protein concentrations were determined 
using the Coomassie brilliant blue dye-binding assay 
(Bradford, 1976). To l-20|jg of protein in a volume 
of lOOpl was added 1ml of colour reagent (10% (w/v)
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Coomassie brilliant blue G, 4.75% (v/v) ethanol,
8.5% (w/v)phosphoric acid). The colour reagent 
(stored at room temperature in the dark) was filtered 
prior to use. After 10 min-lh the absorbance of 
the sample under test was read at 595nm. For each 
assay, a fresh standard curve of Abs vs concentration 
(l-20|jg in 100|j1) of standard protein was prepared
I
from which to read off the concentration of the
1%protein under test. Ovalbumin (E^cm = 7.35 at 280nm) 
was used as the standard protein.
Screening Methods
3.18 Antigen coating for ELISAs
ELISA reactions were carried out using
flat-bottomed (rigid polystyrene) EIA strips
(Titertek, Flow Lab.). Unless otherwise stated,
PBS was used as incubation and washing buffer
throughout. All conditions were optimized for each
assay, details of which are summarized in Fig. 4.
For assays I, II and III wells were coated for 18h
-1
at 4°C using a solution of PHCS (10|jgml ) in 
0.05M sodium carbonate (pH9.8), PBS(pH7.3) or 
0.1M sodium acetate (pH4.2) buffer respectively. 
Plates were then blocked by incubation for 30 min 
at 37°C with 1% (w|v) casein in PBS and washed with 
PBS.
Poly-L-aspartate (assays IV and V) or 
poly-L-lysine (assays VI and VII) coated plates
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were prepared using 50pgml solutions of polymer 
incubated for 30 min at 37°C. After washing, citrate 
synthase was bound at 37°C for lh using alOpgml  ^
solution in PBS (assays V and VII) or carbonate 
buffer (assay IV) or a 5(jgml  ^ solution in acetate 
buffer (assay VI). The plates were then blocked 
with PBS + 1% casein and washed as above.
Plates for the sandwich ELISA (assay VII) 
were coated for 18h at 4°C with rabbit IgG anti-citrate 
synthase (10|jg protein/ml in carbonate buffer) , 
blocked with PBS + 1% casein and washed. Antibody 
coated wells were then incubated with citrate synthase 
(lOpg/ml in PBS) for lh at 37°C and washed.
3.19 ELISA for anti-citrate synthase
Purified mAb, culture supernatants, or 
antisera at appropriate dilution were incubated in 
antigen-coated plates for lh at 37°C. The amounts of 
mAb or antiserum were selected from dilution curves 
and represent values at which all mAbs gave a positive 
response when compared with a normal mouse serum 
control. After washing, alkaline phosphatase-conjugated 
goat anti-mouse IgG (diluted l|l000) was added for 
lh at 37°C followed by further washing and addition 
of substrate (p-nitropheny1 phosphate, lmg|ml in 
10% diethanolamine-HCl buffer, pH9.8). Incubation 
with substrate at room temperature was continued 
until a standard test serum (mouse anti-citrate 
synthase) reached maximum absorbance ( q  ^ = 1.5),
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at which time all reactions were stopped by addition
of NaOH and A*,.,- values determined using a Titertek 405
Uniskan plate reader.
3.20 Antigen coating for immunodot blot assay
All microculture plates were pre-coated with 
PBS + 1% casein, which was also used as incubation 
and blocking buffer unless otherwise stated. Circles 
(5mm diameter) were cut from nitrocellulose filters 
(0.2pm pore size, Schleicher and Schuell), and 
one circle was placed in each well of a microculture 
plate. Citrate synthase solution (40pl, lOOpg/ml 
buffer) was added to the wells and allowed to dry 
onto the nitrocellulose for 18h at 37°C. The 
nitrocellulose was then blocked for 2h at 37°C and 
washed. Antigen was coated in carbonate buffer for 
assay IX, PBS for assay X, or acetate for assay XI.
For the sandwich blot (assay XII), PBS (40(j 1) 
containing rabbit IgG anti-citrate synthase (lOOpg/ml) 
was dried onto nitrocellulose, which was then blocked 
and coated with citrate synthase (lOpg/ml in PBS) 
as above.
3.21 Immunodot blot assay for anti-citrate synthase
Antigen-coated nitrocellulose circles were 
incubated, for 18h at 4°C, with the appropriate 
dilutions of purified mAb, culture supernatants or 
antiserum. After washing, the circles were then 
incubated with conjugate for 18h at 4°C followed
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by substrate for 35 min at room temperature. At
this time a sample (150|j 1) of the supernatant was
removed to a clean microplate for measurement of
A.,... as described above.405
3.22 Antibody sub-class typing
A commercial (Serotec) ouchterlony typing 
method was employed to establish the sub-class 
of each monoclonal antibody. The kit consisted of
an agar plate with pre-bored
wells, as shown, 
together with sheep 
anti-mouse immunoglobulins 
(IgGl, IgG2a, IgG2b, IgG3, I 
75|j 1 of test culture supernatant, or diluted ascitic 
fluid, was placed in the centre well. lOpl of each 
of the six antisera was dispensed into the outer 6 
wells. The plate was tightly closed, and stored 
flat at room temperature, for 24-48h. After this 
time, the immunoprecipitate relevant to the 
immunoglobulin specificity was visible.
Electrophoretic and immunoblotting techniques
3.23 Gradient SDS-polyacrylamide gel electrophoresis
All electrophoreses were performed using a 
Studier-type slab gel apparatus assembled according 
to Hames and Rickwood, 1981#
O




i) Laemmli method (Laemmli, U.K., 1970).
A discontinuous buffer system, containing 
0.1% SDS, was used. The final concentration of 
buffers was: 0.125M Tris-HCl, pH6.8, in the stacking 
gel, 0.375M Tris-HCl, pH8.8, in the resolving gel, 
and 0.025M Tris, 0.192M glycine, pH8.3, in the 
reservoir buffer.
The resolving gel mixtures were made up 
according to table 3$,for either 8-12%, or 8-20% 
gradients, and degased prior to addition of TEMED. 
17.5ml of the required gradient mixtures were dispensed 
into a linear gradient maker (LKB, total capacity 40ml) 
fitted to a peristaltic pump. Using a magnetic 
stirrer for mixing, and a flow rate of 3-5ml/min, the 
gradient resolving gel was poured vertically from 
the top of the gel. Final delivery to the gel was 
through a very thin tube pushed to the bottom, 
centre, of the gel, and gradually retracted to 
keep it above the filling gel surface. 1ml of water 
saturated isobutanol was layered onto the gel, and 
left for 30 min, for polymerization to occur. The 
gel was overlayed with 0.375M Tris-HCl, pH8.8, 
and left overnight, before the stacking gel was 
loaded.
All Tris buffer, and remaining isobutanol, 
were removed from the gel surface. The stacking 
gel mixture was made up according to the recipe in 
table 3a and degased prior to the addition of TEMED.
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Following insertion of the comb into the glass plates, 
the stacking gel was loaded using a Pasteur pipette, 
and allowed to set. Once set, the comb was removed, 
and the gel tranferred to the running apparatus 
(Hames and Rickwood, 1981), with 400ml of buffer 
put in both top and bottom chambers. Reservoir buffer 
was diluted from a ten times concentrated stock 
solution (0.25M Tris, 1.92M glycine, 1% SDS; pH8.3)
Prior to loading the sample, the gel was 
pre-run for 20 min at 80V ( 20mA) with the cathode 
as the upper (sample) reservoir.
The prepared samples (<100|Jl) were loaded 
into the sample slots, using a O-lOOpl Hamilton 
syringe. Electrophoresis was performed at 80V until 
the sample dye had entered the resolving gel, and 
finally at 150V (initially 35mA) until the dye front 
reached the bottom of the gel (4-6h).
ii) Tris-Bicine method
A discontinuous buffer system, containing 
0-1% SDS, was used. The final concentrations of 
buffers was: 0.1M Tris, 0.1M bicine in the stacking 
and resolving gels, and 0.02M Tris, 0.02M bicine 
in the reservoir buffer.
The resolving gel mixtures were made up 
according to table 3]b for either 8-20%, or 8-25% 
gradients, and degased prior to the addition of 
TEMED. The resolving gel was poured exactly as for 
the 'Laemmli method', and overlayed with 1ml of 
water-saturated isobutanol. When set, the gel surface
Table 3 Recipes for gel preparation for Laemmli and Tris/bicine systems.
(a) Laemmli method
Resolving Gel Stacking gel
8% 12% 20% 3. 75%
Sucrose (=2.7ml Vol.) - 4. 5g 4. 5g -
3M Tris HC1 pH8.8 3.75ml 3.75ml 3.75ml -
0.5M Tris HC1 pH6.8 - - - 5. 0ml
Aery1amide/bisaery1amide 
(30%/0.8%) 8. 0ml 12.0ml 20.0ml 2.5ml
Water 17.05ml 10.55ml 2.55ml 11.3ml
1.5% ammonium persulphate 0.7ml 0.7ml 0.7ml 1.0ml
10% SDS 0. 3ml 0. 3ml 0. 3ml 0.2ml
TEMED 10|Jl lOpl 10 M1 15 |J 1
Total Volume 30ml 30ml 30ml 20ml
Reservoir buffer: 0.025M Tris, 0.192M glycine, 0.1% SDS, pH 8.3
Table 3
(b) Tris/Bicine method
Resolving Gel Stacking Gel
8% 20% 25% 3.75%
Sucrose (=2.7ml Vol.) - 4. 5g 4. 5g -
1M Tris, 1M Bicine 3. 0ml 3. 0ml 3. 0ml 2. 0ml
Aery1amide/bisaery1amide 
(47.6%/2.4%) 4. 8ml 12.0ml 15.0ml 1. 5ml
Water 21.2ml 11.3ml 8. 3ml 15.3ml
1.5% ammonium persulphate 0.7ml 0.7ml 0.7ml 1.0ml
10% SDS 0.3ml 0.3ml 0. 3ml 0. 2ml
TEMED 10|jl 10\il 10|Jl 15 |J 1
Total Volume 30ml 30ml 30ml 20ml
Reservoir buffer: 0.02M Tris, 0.02M Bicine, pH8 . 2 , 0*1 M SDS.
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was washed with water, which was subsequently removed. 
The stacking gel mixture was made up as in table 31p 
and degased prior to addition of TEMED. Following 
insertion of the comb into the glass plates, the 
stacking gel was loaded and allowed to set, after 
which the gel was treated as under the 'Laemmli 
method'. The pre-run was for 20 min at 80V ( 12mA). 
Electrophoresis of the sample was performed at 150V 
( 20mA) through both the stacking gel and resolving 
gel, until the dye front reached the bottom of the 
gel (17-20h).
3.24 Sample preparation for SDS-Page
The procedure was identical for both the 
Laemmli and Tris-bicine methods. The sample buffer 
was prepared by dissolving 1.51g of Tris and 20ml 
glycerol in 35ml water, and adjusting to pH6.75 
with concentrated hydrochloric acid. Following this,
4g SDS, 10ml 2-mercaptoethanol and 4mg bromophenol 
blue were dissolved in it, and the volume adjusted 
to 100ml.
Salts were removed from the samples by 
dialysis against 20mM Tris, pH8.0, or 125mM Tris, 
pH6.8. Samples which were freeze-dried were 
reconstituted with water. To the sample, in up to 
50pl of Tris buffers, or water, was added an equal 
volume of sample buffer. The sample was boiled for
2-3 min, and spun in a microfuge at 17,000g for 
5 min prior to loading the supernatant onto the
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gel. Up to lOOpl of sample was loaded per track 
(0.9mmdiam., 1.8mm depth).
3.25 Electrophoretic transfer of proteins from 
PAGE gels to nitrocellulose
The blotting apparatus used was similar to 
TMthe Bio-Rad Trans-Blot Cell, but had 2 graphite 
plates (175mm x 222mm x 10mm) as the electrodes.
After running as described in section 3.23, 
the resolving gel was removed carefully from the 
apparatus and tracks were marked with a scalpel. The 
gel was rinsed in distilled water and washed for 
10 min in blotting buffer (2mM sodium acetate, 5mM 
MOPS, 20% ethanol, pH7.5). Nitrocellulose strips were 
cut to the same dimensions as the gel tracks, and 
washed for 10 min in the blotting buffer.
The gel was placed on a Bio-Rad Transblot 
sandwich pad, and the nitrocellulose strips were 
carefully placed over their corresponding tracks on 
the gel. The second sandwich pad was placed over 
this, and the apparatus was placed in the blotting 
tank, with the gel towards the cathode, and the 
nitrocellulose towards the anode. Electrophoretic 
transfer was carried out for 2h at 60V/0.55A, with 
stirring, and using a water cooling coil in the 
centre of the apparatus.
77
3.26 Passive transfer of proteins from PAGE gels 
to nitrocellulose









The buffer used in the reservoirs was 
1 OmM Tris/HCl,pH8.0,and transfer was performed for 
between 36h and 48h at room temperature.
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3.27 Staining polyacrylamide gels
Tracks of gel to be stained for protein were 
incubated overnight at room temperature on a shaker, 
with 0.025% coomassie blue R stain in methanol/
water/acetic acid (5:5:1). Destaining was achieved 
using several changes of 5% methanol, 10% acetic acid, 
85% water.
3.28 Amido black staining of nitrocellulose bound 
protein
Nitrocellulose strips with blotted protein 
bands were incubated for 5 min with 1% naphthol 
blue-black in methanol/acetic acid/water (5:1:4). 
Destaining was performed in methanol/acetic acid/water 
(5:1:4).
3.29 Immunoblotting of nitrocellulose bound protein
Following electrophoretic transfer, 
nitrocellulose strips were incubated at 4°C with 
1% casein in PBS overnight to block non-specific 
binding. Strips of 5mm width were fitted into
8-well multichannel pipette reservoirs for convenience 
for all further incubations.
Monoclonal antibodies were diluted to 100|jg/ml, 
and sera used at a 1/50 or 1/100 dilution, in 1% 
casein/PBS. 4ml of antibody solution were used in 
each reservoir, and these were incubated for 2h 
on a shaker at room temperature. Strips were washed
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for 5 x 10 min in 1% casein/PBS and incubated with 
goat anti-mouse immunoglobulins (polyvalent) for 2h 
at room temperature, with shaking. Strips were then 
washed for 5 x 10 min with PBS (azide free).
Colour was developed using: 0.02% 3-amino-
9-ethyi carbazole, 5% dimethyl formamide, 0.00025% 
thiomersal, 0.03% *^02 in 0.05M sodium acetate buffer, 
pH5.0, as substrate.
Fragmentation of PHCS
3.30 Limited proteolysis of PHCS
Proteolysis of PHCS by protease type VII, 
subtilisin BPN', chymotrypsin type II, from bovine 
pancreas and trypsin type III-S from bovine pancreas 
was performed at 25°C, as described by Bloxham et 
al, 1980 and Lill et al, 1984).
Prior to the reaction, PHCS was dialysed 
against 0.1M Tris-HCl, pH8.0. The final incubation 
mixtures contained PHCS (lmg|ml), a protease 
(subtilisin at 2|jg/ml, chymotrypsin at 2pg/ml or 
trypsin at lOpg/ml), and palmitoyl CoA (250|JM for 
chymotrypsin and subtilisin, 60|jM for trypsin) in 
50mM Tris-HCl, pH8.0. The reaction was stopped in 
all cases by the addition of two volumes of reaction 
mixture to 1 volume of lOmM phenylmethane-sulfonyl 
fluoride. Immediately after this, cold acetone 
(10 volumes) was added, and the digested PHCS fragments 
were precipitated by incubation at -20°C for lh
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followed by centrifugation in a microfuge at 17,000g.
The samples were reconstituted in water
prior to the addition of PAGE sample buffer (section
3.24) .
3.31 Chemical fragmentation of PHCS
Mild acid cleavage at asparty1-proly1
peptide bonds was performed according to Rittenhouse
- 1
and Marcus, 1984. PHCS (0.12mgml ) was incubated
at 110°C in the presence of 15mM HC1. The reaction 
was stopped by rapid cooling and freeze-drying of the 
sample. The samples were reconstituted in water 
prior to the addition of PAGE sample buffer, section 
3.24.
Hydroxylamine cleavage of asparaginyl- 
glycine bonds was performed according to Bornstein,
1970 and Bloxham et al, 1982.
Immediately prior to use, a reaction solution 
containing 1.8M hydroxylamine, 5.3M guanidine 
hydrochloride in 0.2M K^CO^, pHIO, was prepared as 
follows. NH2OH.HCI (3.48g) and guanidine.HC1 (14.32g) 
were dissolved in 13ml of H2O in an ice bath. 2.5ml 
of 12.5N NaOH was added slowly with vigorous stirring, 
followed by addition of 5ml of lMf^CO^. The pH of the 
solution was titrated to 10.5 with additional NaOH, 
and the volume adjusted to 25ml.
For fragmentation to occur, 4 volumes of 
reaction solution were added to 1 volume of PHCS 
(1.60mg|ml), and the mixture was incubated at 45°C
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for 7h. Following digestion, the sample was immediately 
dialysed at 0°C against 50mM Tris-HCl, pH8.0, 0.1% SDS, 
prior to the addition of PAGE sample buffer (section
3.24) .
3.32 Preparation of mAb immunosorbent columns
The cyanogen bromide activation of Sepharose- 
4B, and subsequent coupling of mAbs, were performed 
according to March et al, 1974.
One volume of beads (Sepharose 4B), one 
volume of water, and two volumes of 2M sodium 
carbonate were mixed by stirring slowly. The rate 
of stirring was increased and 0.25 volumes of an 
acetonitrile solution of cyanogen bromide (0.9g 
cyanogen bromide per ml of acetonitrile) was added 
quickly. The slurry was stirred vigorously for 1.75 
min, after which it was filtered over a coarse 
sintered-glass funnel and was washed with 10 volumes 
each of 0.1M sodium bicarbonate, pH9.5, water and 
0.2M sodium bicarbonate, pH9.5. The filtered Sepharose 
was transferred to a plastic beaker containing one 
volume of 0.2M sodium bicarbonate:, pH9.5, and one 
volume of mAb in 0.2M sodium bicarbonate, pH9.5 
(3.3'mgmAb per ml of Sepharose). Coupling was performed 
for 20h at 4°C. After coupling, the beads were washed 
with 0.1M sodium bicarbonate (pHlO.O) and then 
incubated with 4 volumes of 1% casein in 0.2M sodium 
bicarbonate for 18h at 4°C. Beads were washed with 
10 volumes each of 0.1M sodium acetate (pH4.0),
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PBS and 0.1M sodium bicarbonate (pHIO). The coupled 
beads were then packed into columns of approximately 
1.5ml volume.
Before use, columns were washed with 10 
volumes each of 1% casein in PBS, 0.5M NH^OH, pH10.8, 
and PBS. Columns were stored and run at 4°C.
3.33 MAb immunosorbent chromatography
The sample to be loaded was reconstituted
or equilibrated in PBS. For a column of 1.5ml volume,
the sample (300|Jg protein in 1ml PBS) was loaded onto,
and left to equilibrate in, the column for 6h. The
columns were washed with 10 column volumes each
of PBS, and 20mM Tris-HCl, pH8.0. The bound material
was eluted with 2 column volumes of 0.5M NH.OH,4
pH10.8, and freeze dried. The freeze dried eluants 
were?reconstituted in water prior to the addition 
of PAGE sample buffer, section 3.24. Columns were 
re-equilibrated into PBS for storage.
Enzyme inhibition studies
3.34 Assay of citrate synthase activity
i) Acetyl CoA was prepared by the method 
of Stadtman, 1975. lOmg CoASH (free acid) was dissolved 
in 1ml of water, cooled to 0°C, and 0.2ml of 1M KHCO^ 
was added to bring the pH to 7.5. 0.16ml of 0.1M 
acetic anhydride was added and the mixture was allowed 
to stand for 10 min. The acetylation was assumed 
to be complete if the acetyl CoA preparation was
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unable to react with lOmM 5 , 5'-dithiobis (2-nitrobenzoic 
acid) (DTNB).
ii) The enzymic assay for citrate synthase
was performed as per Srere et al, 1963. All assays were
carried out at 25°C. Unless otherwise stated the assay
mixture contained (final concentrations) 0.15mM acetyl
CoA, 0.2mM oxaloacetate and O.lmM DTNB, in 20mM Tris-
HCl, pH8.0/lmM EDTA. The reaction was monitored by
measuring the increase in absorbance at 412nm due
to the reaction of CoA with DTNB producing the yellow
coloured thio-nitrobenzoate anion (E..^ 13,600L.moll cm ^412
at pH8 . 0) .
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4.1 Comparison of immunization procedures
Four mice were given primary immunizations 
with PHCS, two intraperitoneally and two subcutaneously. 
After a period of 1 month, mice were boosted. Seven 
days later mice were tail bled, 20(J1 of blood being 
taken from each mouse. Sera obtained from the mice 
were assayed at dilutions of 1/100 by ELISA I. The 
results following a 10 min substrate incubation 
are shown in table 4.1.
These results show that intraperitoneal and
r
subcutaneous primary immunizations were equally 
effective in inducing the production of antibodies 
against PHCS.
4.2 Production of mAb secreting cell lines A-E
One of the two subcutaneously primed mice, 
referred to above, was boosted to provide the spleen 
for fusion. The fusion was performed as in section 3.8, 
and the cells were plated out onto 5 microtiter 
plates.
446 of the 480 possible wells showed colony 
growth, equivalent to 93% of wells. The fraction of 
wells with growth follows the Poisson distribution 
(Goding, 1980).
Using this theorem f (0) = e where f(0) is 
the fraction of wells with no growth and X is the 
average number of clones per well. It is estimated 
that on average each well of the fusion contained 2.65 
growing colonies.
8 6
Table 4.1 Anti-PHCS activity shown by sera from
















Anti-PHCS activity, measured by ELISA I, 





Using ELISA I, all wells showing growth were 
assayed for anti-PHCS activity. Supernatants from 31 
wells were strongly positive (Abs^g,-> 0.3 after 30 min 
incubation with substrate) and 25 wells were weakly 
positive (Abs^Qj-> 0.15). This suggests that 4.4% of all 
growing colonies were secreting antibodies reactive with 
PHCS.
5 cell lines A-E were produced, cloned and 
grown up in mice, from which ascitic fluid was collected. 
During cloning, supernatants were assayed by ELISA I.
The cloning efficiencies are shown in table 4.2.
4.3 Production of mAb secreting cell lines F, G,
H, K, L and M
A mouse was primed intraperitoneally, boosted 
7 days later and tail bled (20(jl blood) 7 days after 
this. The serum obtained was assayed by ELISA VIII 
and proved to be positive for anti-PHCS when compared 
to normal mouse serum. Two days after tail bleeding, 
the mouse was boosted and 4 days following this its 
spleen cells were used in a fusion. The fusion was 
performed as in section 3.8 and was plated out onto 
5 microtiter plates.
Supernatants of two plates were screened 
for the ability to inhibit enzyme activity, when 
incubated for 15 min with 6ng of PHCS. The reaction 
was performed in ELISA plates and started by addition 
of acetyl CoA and oxaloacetate (to final concentrations 
of lOpM). Following a 20 min incubation, plates were
Table 4.2 Cloning efficiencies of the 5 cell lines A-E















% +ve % +ve % +ve % +ve % +ve % +ve % +ve % +ve
33 21 22 17 42 36
80 33 80 22 80 42A N/A N/A
= 41% = 64% = 28% = 77% = 53% = 86%
24 2 21 9 29 26
r> 114 24 80 21 80 29
N/A N/A
= 21% = 8% = 26% = 43% = 36% = 89%
47 26 48 26 34 24 21 15
c 80 47 80 48 80 34 80 21
= 59% = 55% = 60% = 54% = 43% = 71% = 26% = 71%
31 3 28 12 32 32
80 31 80 28 80 32U N/A N/A
= 39% = 10% = 35% = 43% = 40% = 100%
8 7 21 20 18 15
80 8 80 21 80 18th N/A N/A
= 10% = 88% = 26% = 95% = 23% = 83%
Cell growth is expressed as the percentage of seeded wells which grow colonies. The percentage
of wells showing colony growthtogether with anti-PHCS activity is also shown.
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read at 405nm on an ELISA reader. Two cell lines
(clones L and M) appeared to be secreting inhibitory
antibodies. Following incubation with supernatants
from these cell lines, PHCS gave a rate of reaction
of 0.02AA^Qj-/min as compared with a rate of
0 . 027AA. ni_/rnin following incubation with antibody 
4 U D
free supernatants, and a rate of 0. 002a A^q ,_/min for 
no-enzyme controls.
The three further plates were screened using 
ELISA VIII, taking an of >0.150 after 30 min
incubation with substrate as positive. By this screen 
a further 4 cell lines were chosen, F, G, H and K.
All six cell lines from this fusion were 
screened by ELISA VIII during cloning. The cloning 
efficiencies are shown in table 4.3.
4.4 Production of monoclonal antibodies from ascitic 
fluid
In subsequent chapters, the mAbs are named 
after the cell line from which they are produced.
Table 4.4 shows the number of mice from 
which ascitic fluid was collected for each cell line, 
and the quantity of mAbs obtained following ammonium 
sulphate precipitation.
4.5 MAb sub-class typing
Partially purified mAbs were used at a 
concentration of 5|jg/ml, and the assay was performed 
as described in section 3.22.
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Table 4.3 Cloning efficiencies of cell lines F, G,
H, K , L and M
Once cloned Twice cloned








34 24 9 4
F 80 34 80 9
= 43% = 71% = 11% = 44%
15 6 23 16
M 80 15 80 23
= 19% = 40% = 29% = 70%
40 15 19 9
G 80 40
80 19
= 50% = 38% = 24% = 47%
27 12 17 8
H 80 27 80 17
= 34% = 44% = 21% = 47%
47 35 42 38
K 80 47 80 42
= 59% = 74% = 53% = 90%
38 30 51 32
L 80 38 80 5l
= 48% = 79% = 64% = 63%
Cell growth is expressed as the percentage 
of seeded wells which grew colonies. The percentage 
of wells showing colony growth together with anti-PHCS 
activity is also shown.
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Table 4.4 Quantities of mAbs obtained from ascites
mAb no. mice Protein after














Two mAbs, B and C, showed only a single 
preqipitin line between the mAb well and the well 
containing sheep anti-mouse IgGl. 8 mAbs (A, D, E,
F, G, H, K, L and M) were similarly shown to be IgM.
4.6 Further purification of mAbs
Further purification of mAbs A-E was attempted 
using insolubilized Protein A, by the method described 
in section 3.16, while monitoring the fractions collected 
(following neutralization by dropwise addition of 
2M Tris base) by ELISA I.
MAbs A, D and E are of IgM class and did 
not bind to the insolubilized Protein A. MAb C, an IgGl, 
bound only slightly and it was not considered worthwhile 
trying to purify it further by this method.
MAb B, an IgGl, was purified using immobilized 
Protein A. 98mg of partially purified mAb B, in 4.5ml 
of 0.1M sodium phosphate buffer, pH8.0, was loaded 
onto a 15ml Protein A affinity column. Washing and 
elution was performed as in 3.16. Substantial anti-PHCS 
activity was found in the 0.1M sodium citrate pH6.0 
fraction, which contained 72.5mg protein. No anti-PHCS 
activity was detected in the 0.1M phosphate washing 
buffer, the citrate eluting buffers pH4.5, pH3.5, 
or in the final 0.1M citric acid wash. The combined 
protein eluted by other washing and eluting buffers 
w a s = 40mg. This indicates that only a 1.5 fold 
purification was achieved using Protein A affinity
chromatography and therefore this method was not adopted 
routinely.
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4.7 Purity of monoclonal antibodies
The purity of mAbs was assessed by SDS PAGE 
under reducing conditions (section 3.23i). An 8-12% 
acrylamide gradient gel was used. Normal mouse serum 
was included on the gel together with standards 
(fig 4.1).
MAb B, an IgGl purified on immobilized Protein 
A, showed bands corresponding to light chains (25K),
Y chains (52K) and 2 feint bands at 75K and 100K 
(track 6). MAb C, an IgGl partially purified using 
ammonium sulphate, showed these bands plus a band 
corresponding to human albumin (68K) and a feint band 
at 70K (track 5).
Track 3 is a sample representing all of mAbs 
D, E, F, G, H, L and M, which all show bands at 25K 
(light chains), 67K (albumin) and 71-73K (y chain).
MAb A shows these bands plus a band at 53K.
All mAb tracks showed a substantial increase 
in purity over the normal serum track. The major 
non-immunoglobulin contaminant being albumin, which 
by the intensity of its staining was estimated as 
comprising less than 10% of the total protein on tracks
3-5.
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Fig 4.1 Schematic representation of an 8-12% PAGE 
gel to show the purity of mAbs
1 2 3 4 5 6
Mol
Track 1 molecular weight markers; B-galactosidase (116K), 
bovine serum albumin (66K), ovalbumin (45K), 
glyceraldehyde 3-phosphate dehydrogenase (36K), 
carbonic anhvdrase (29K) and bovine trypsin inhibitor 
(20K).
Track 2 normal mouse serum, track 3 mAbs D, E, F, G, M,
L or M, track 4 mAb A, track 5 mAb C, track 6- mAb B.
95
4.8 Discussion
The fusion partner X63-Ag8.655 was chosen 
as it has entirely lost immunoglobulin expression, 
and therefore does not secrete immunoglobulin heavy 
or light chains. The generation of hybridomas was 
performed by the method of Fazekas de St. Groth and 
Scheidegger (1980), who have optimized the techniques 
presently used to produce mouse monoclonal antibodies.
Most cell fusions are now performed with 
PEG (Zola and Brooks, 1982). The use of DMSO however, 
is not so well accepted as being necessary. Fazekas 
de St. Groth and Scheidegger (1980) reported no 
improvement in the number of hybridomas on addition 
of DMSO; however the reverse was found by Westerwoudt 
et al, 1984. We included 5% DMSO as a harmless 
precaution in the fusion mixtures.
Both PEG and DMSO markedly decrease the 
surface potential of biological membranes (Maggio et 
al, 1976) and cause charge neutralization of the cell 
membrane. Dehydration may also have a role in PEG- 
mediated fusion (Knutton and Pasternak, 1979).
With an electron microscope small cytoplasmic 
bridges can be observed between cells about 4 min 
after exposure to PEG (Knutton, 1979). This 
intercytoplasmic communication begins 1-3 min after 
dilution of PEG (Wojcieszyn et al, 1981). Water-soluble 
cytoplasmic proteins do not diffuse from one cell 
to another until PEG is removed (Westerwoudt, 1985). 
Cytoplasmic mixing is optimal at 37°C and is complete
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at 4h (Wojcieszyn et al, 1983). At this stage a 
heterokaryon exists (with two or more nuclei). During 
the next cell division the nuclei fuse and a hybrid 
cell results (Goding, 1980) .
Following HAT selection, a fusion mixture 
would contain cells secreting mAbs against PHCS, cells 
secreting mAbs against irrelevant antigens and cells 
secreting no antibody. It is necessary to clone cells 
as soon as they have been screened for antibody 
production in order to separate out the mAb secreting 
cells required.
The method of cloning cells by limiting 
dilution does not in practice always generate Abs 
that are truly monoclonal (Galfre and Milstein, 1981). 
In this study we used a single cell transfer method 
which should produce monoclonality following each 
cloning step (Gagnon and Raymond, 1985).
Immediately following hybridisation, the 
hybrid cells will have approximately 80 chromosomes 
and as they divide they may randomly loose some of 
these chromosomes. Plasma cells may devote up to half 
their total protein synthesis to that of immunoglobulin 
(Goding, 1980). A cell which sheds this burden, by 
loss of chromosomes, will in all likelihood grow 
faster. Thus there will be a strong tendency for 
cultures to be overgrown by non-producing cells, 
emphasizing the need for early cloning.
From my results of the number of growing 
wells positive for anti-PHCS activity at each stage 
of cloning, an increase is seen with increased cloning.
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Summing these results for the 11 hybridomas it is seen 
that following the first cloning 181 of 344 cells 
were secreting anti-PHCS Abs (53%) . This percentage 
is a reflection of the fact that a positive antibody 
secreting well after fusion may contain colonies 
derived from more than one fused cell (c.f. 2.65 
colonies/well for first fusion). These will be carried 
through at the first cloning. Following the first 
cloning by single cell transfer, each well now contains 
a colony derived from one single cell. Subsequent 
clonings from positive anti-PHCS secreting wells 
might be expected to yield only anti-PHCS positive 
colonies. However my results (summed for 11 hybridomas) 
indicate that after two clonings only 191 of 301 
colonies have anti-PHCS activity (63%) , and after 
three clonings 133 of 155 colonies (86%) have anti- 
PHCS activity.
These results show that some cells derived 
from secreting parent cells lose their ability to 
secrete immunoglobulins. This may be by chromosome 
loss as previously discussed. The increase in the 
percentage of growing colonies secreting anti-PHCS 
activity seen with increasing cloning does however 
show that this technique is very useful in strengthening 
a hybridoma cell line.
As soon as feasible, aliquots of cells 
were preserved in liquid nitrogen. This was to provide 
backup cell stocks at each stage of cloning to ensure 
against loss of cells by overgrowth of non-producers
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or by infections.
Macrophages(peritoneal cells) were used 
as feeder cells at all stages when cells were transferred 
from one culture vessel to another, or when they were 
to be grown at low density (ie. upon cloning).
Macrophages are able to clear dead cell debris from 
cultures and probably also secrete 'growth factors' 
which may stimulate the growth of hybridomas. Where 
growth of hybridomas is at low density, use of 
macrophages creates an important increase in overall 
cell concentration and may also remove toxic by­
products from the medium (Zola and Brooks, 1982).
The ratio of IgG to IgM secreting hybridomas 
may be dependent on the method of immunisation.
In this study an initial subcutaneous immunisation
followed by two boosters at weeks 5 and 6 gave 2
IgGl secreting hybridomas and 3 IgM secreting hybridomas.
The subsequent fusion involving intraperitoneal
priming and two booster injections at weeks 2 and 3
led to 6 IgM secreting hybridomas. It has been suggested
that increased time of immunisation, multiple boosters
and even intra-splenic immunisation, may be used
to increase the proportion of IgG secreting hybridomas
obtained.
The assessment of the purity of the mAbs 
(following ammonium sulphate purification) shows 
the major non-immunoglobulin contaminant to be albumin. 
The content of specific mAb, within the immunoglobulin 
fraction of ascitic fluid purified by ammonium 
sulphate precipitation, has not been assessed. It
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is however generally accepted that ascitic fluid 
containing mAbs is highly specific and can be used 
directly in immunochemical studies (Goding, 1980, 
Mierendart, 1983, Friguet, 1983).
Using the different screening methods 
described, this work has generated a library of 
11 mAbs. The library of mAbs, to be used further 
in studying antigenicity, is required to have a 
large range of different specificities. Various 
screening methods were used as the use of different 
screening methods enables selection of mAbs with 
a wide range of specificities, discussed further 
in chapter 5.
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5.1 Choice of optimum conditions for ELISAs and 
immunodot blots
On an ELISA plate it is convenient to vary 
up to two parameters simultaneously, one in either 
direction, to determine the optimum combination of 
the two for future use. This is called a checkerboard 
system.
Using a series of dilutions of mouse anti-PHCS
serum and varying the concentration of coating antigen
in assays I-VII, the conditions for antigen coating
were optimized. For the sandwich assay (VIII) both
the concentration of coating rabbit IgG anti-PHCS
and the following antigen, were varied for optimization.
Figures 5.1 and 5.2 show results for the
optimization of assays IV and V as examples. From
these results optimal sensitivity was achieved by
-1
using PHCS at 10 or 20pgml for both assays. It
was decided to use PHCS routinely with poly L-aspartate
-1
pre-coated plates at lOpgml m  carbonate buffer, 
for assay IV, and at 10(jgml  ^ in PBS for assay V.
Similar experiments for the other assays led to the 
optimum coating conditions given in section 3.18 
and 3.20.
-1
The final substrate concentration (lmgml 
p-nitropheny1 phosphate) was chosen, as it provides 
the substrate in excess, such that a linear rate 
of change in absorbance is given up to a value of 











Fig 5.1 The effect of varying the concentration 
of PHCS on the sensitivity of ELISA IV 
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Fig 5.2 The effect of varying the concentration 
of PHCS on the sensitivity of ELISA V








Dilution of mouse anti-PHCS serum
104
5.2 Hybrid screening using ELISAs IV and VI
ELISA systems with poly L-aspartate or 
poly L-lysine spacers (assays IV and VI) were compared 
as alternative initial screens for anti-PHCS producing
hybridomas. Following cell fusion, a 96 well culture
6 7plate containing 2 x 10 myeloma cells and 2 x 10
immunized spleen cells in HAT medium was incubated
for three weeks,at which stage supernatants were
harvested and cultures fed with fresh medium. Supernatant
harvesting was continued at two day intervals and
samples were stored at -20°C prior to assay.
Pooled samples from each of the 56 colony- 
containing wells were assayed for anti-citrate synthase 
using assays IV and VI. An average absorbance (of 
duplicate assays) at 405nm of greater than 0.09 units 
following a 30 min incubation with substrate,was 
considered positive. The results (table 5.1) show 
that although certain colonies were identified as 
anti-PHCS secretors by both assays, other colonies 
were identified by only one of the assays. Thus of 
the 14/56 colonies which produced anti-PHCS, 4/14 
were identified only by assay IV, 4/14 only by assay 
VI and 6/14 by both assays. This suggests that neither 
of the assavs used for screening is able to detect 
all antibody-producing cultures.
5.3 Comparison of solid phase immunoassays
The relative reactivities of the mAbs were 





















Anti-PHCS activity in culture supernatants was measured
using assay IV or assay VI. Positive reaction was
defined as an increase in A.-.,, of >0.09 after incubation405
with substrate for 30 min.
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for ELISAs and immunodot blots given in section 3.18 and
3.20. MAbs were used at concentrations of 100, 10, 1 and 
-1
O.lpgml . The results were expressed as graphs of A^q .^
versus concentration of antibody for assays I-XII
(figs 5.3-5.14). The antibody activity for each mAb (at 
-1
100|jgml concentration) was expressed as a percentage 
of the value given by a 1/50 dilution of mouse
serum anti-PHCS. The data are presented in the form of 
histograms (figs 5.15-5.18).
From these data it can be seen that when direct 
coating assays (I — 111) were compared, where the pH of the 
antigen-coating buffer was varied, little difference was 
seen in the relative reactivity of each mAb between the 
different assays (figs 5.3, 5.4, 5.5 and 5.15). Similar 
relative reactivities were also observed when comparing 
the use of poly-L-aspartate as spacer (figs 5.6, 5.7 and 
5.16) with direct coating (fig 5.15). In all these 
assays, mAbs B, C, E and F show strong reactivity 
whereas A, H and L appear relatively weak. In procedures 
VI and VII, where poly-L-lysine was used as spacer, mAbs 
F and E gave a strong reaction, as did B and C in assay 
VI (figs 5.8, 5.9 and 5.16). MAbs H and L, which were 
very weak responders in assays I-V, gave a stronger 
response in assay VI and VII.
The sandwich ELISA (assay VII), in which antigen 
was immobilized via polyclonal rabbit anti-PHCS, showed 
increased reactivity with all mAbs (figs 5.10 and 5.17) 
when compared with direct assays. Clones B, D, E,
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Fig 5.3 Dilution curves for mAbs in ELISA I (PHCS coated directly at pH9.8). Mouse anti-PHCS
3 4serum# was used at dilutions of 1/50, 1/500, 1/5x10 , and 1/5x10 .
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Fig 5.4 Dilution curves for mAbs in ELISA II (PHCS coated directly at pH7.3) 
Mouse anti-PHCS • was used at dilutions of 1/50, 1/500, 1/5x10^ and l/5xl04 .
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Fig 5.5 Dilution curves for mAbs in ELISA III (PHCS coated directly at pH4.2 
Mouse anti-PHCS serum 
Substrate incubation was for 30 min.
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Fiq 5.6 Dilution curves for mAbs in ELISA IV (poly-L-asp pre-coated plate coated with PHCS at
— ----  3 4
pH 9.8 i . Mouse anti-PHCS serum • was used at dilutions of 1/50, 1/500, 1/5x10 and 1/5x10
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Fig 5.7 Dilution curves for mAbs in ELISA V 
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(poly-L-asp pre-coated plate coated with PHCS 
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Fig 5.8 Dilution curves for mAbs in ELISA VI 
pH 4.2). Mouse anti-PHCS serum • was used at 
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Fig 5.9 Dilution curves for mAbs in ELISA VII (poly-L-lys pre-coated plate coated with PHCS
at pH7.3). Mouse anti-PHCS serum 
Substrate incubation was for lh.
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Fig 5.10 Dilution curves for mAbs in ELISA VIII (sandwich assay). Mouse anti-PHCS serum • was 
used at dilutions of 1/50, 1/500, 1/5x10^ and 1/5x10^.
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Fig 5.11 Dilution curves for mAbs in immunodot-blot assay IX (PHCS coated directly at pH9.8). 
Mouse anti-PHCS serum# was used at dilutions of 1/50, 1/500, 1/5000 and 1/5x10 .
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Fig 5.12 Dilution curves for mAbs in immunodot blot assay X (PHCS coated directly at pH7.3). 
Mouse anti-PHCS serum • was used at dilutions of 1/50, 1/500, 1/5000 and 1/5x10^.
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Fig 5.13 Dilution curves for mAbs in immunodot blot assay XI (PHCS coated directly at pH4.2).
4
Mouse anti-PHCS serum# was used at dilutions of 1/50, 1/500, 1/5000 and 1/5x10
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Fig 5.14 Dilution curves for mAbs in immunodot blot assay XII (sandwich assay). Mouse anti-PHCS 




Fig 5.15 Histograms showing the relative activities of
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Antibody clone
The activity of each mAb (at lOOpgml 1 concentration) 
is expressed as a percentage of the value given




Fig 5.16 Histograms showing the relative activities
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Antibody clone
The activity of each mAb (at lOOpgml  ^ concentration) 
is expressed as a percentage of the value given
by a 1/50 dilution of mouse anti-PHCS serum.
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Fig 5.17 Histogram showing the relative activities
of mAbs in the sandwich ELISA, assay VIII
A B C D E F G H K L  
Antibody clone
The activity of each mAb (at lOOpgml 1 concentration) 
is expressed as a percentage of the value given
by a 1/50 dilution of mouse anti-PHCS serum.
1 2 2
Fig 5.18 Histograms showing the relative activities
of mAbs in assays IX - XII
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The activity of each mAb (at lOOpgml 1 concentration) 
is expressed as a percentage of the value given
by a 1/50 dilution of mouse anti-PHCS serum.
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of positive control mouse antiserum and all mAbs gave 
>17% of the control response.
When the immunodot blot assay (XI) was used, 
mAbs B, C and M responded strongly (figs 5.13 and 
5.18). When the pH of the coating buffer was varied 
(assays IX and X) these clones remained positive, 
and in addition clone A was detected (figs 5.11, 5.12 
and 5.18). All mAbs were detected using the sandwich 
immunodot blot (assay XII, figs 5.14 and 5.18), although 
B and C were less reactive than in the direct coating 
immunoblots. In general, the immunodot blot assays 
were much less sensitive than the ELISA methods.
5.4 ’Open1 and 'Closed' conformations of PHCS used 
in sandwich ELISAs
Two variations of sandwich ELISAs (assay VIII) 
were performed. In one, the enzyme was incubated with 
a rabbit anti-PHCS pre-coated plate as in section 
3.18. In the other, the enzyme (lOpgml )^ was pre­
incubated with oxaloacetate (30mM) for 2 min prior 
to the solution being incubated with a rabbit anti-PHCS 
pre-coated EIA plate as in section 3.18.
The relative reactivities of the mAbs were 
compared using the two sandwich ELISAs (figs 5.19 
and 5.20). The results are presented in the form of
histograms of the relative signals given by mAbs used
-1
at a concentration of lOO^igml (fig 5.21).
From these data it can be seen that a 
substantial drop occurs in the relative reactivities 
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1 2 6
Fig.5.21 Histograms showing the relative activities 
of mAbs in sandwich ELISAs in which PHCS is 
presented in the 'open' and 'closed1 forms
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a) FHCS untreated prior to coating.
b) PHCS pre-incubated with oxaloacetate prior to 
coating.
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sandwich ELISA which includes oxaloacetate, with one 
that does not. The relative signal given by mAb E 
in the ELISA with oxaloacetate present is 89% of that 
seen in the ELISA without oxaloacetate. This is only 
a small drop. The relative signals given by all the 
other mAbs in the ELISA with oxaloacetate present 
are only 43-63% of their respective signals in the 
ELISA without oxaloacetate.
5.5 The effect of SDS and 2-mercaptoethanol on the 
presentation of PHCS in sandwich ELISAs
Four sandwich ELISAs were performed essentially 
as described in section 3.18, differing only in the 
ways in which the PHCS was treated prior to incubation 
with a rabbit anti-PHCS pre-coated EIA plate. The 
different treatments are listed below.
1) PHCS incubated for 5 min in PBS
2) PHCS boiled for 2 min in 4% (w/v) SDS/PBS, and 
subsequently cooled.
3) PHCS boiled for 2 min in 10% (w/v) 2-mercaptoethanol/
PBS, and subsequently cooled.
4) PHCS boiled for 2 min in SDS/PAGE sample buffer
(section 3.24) and subsequently cooled.
The relative reactivities of mAbs were compared 
at a concentration of lOOpg/ml. A control normal mouse 
serum was used at a dilution of 1/100. For convenience 
the enzyme-conjugate used in these ELISAs was horse 
radish peroxidase-conjugated goat anti-mouse IgG
1 2 8
(diluted 1/1000). Incubation with substrate (0.01%
3,3-5,5-tetramethylbenzidine, 1% dimethylsulphoxide 
in 0.1M sodium acetate/citric acid buffer pH6.0) was 
continued for 30 min, after which the reaction was 
stooped by addition of 50pl of 2M sulphuric acid.
The results are shown in figs 5.22 
as histograms representing the final absorbance for 
each mAB.
From the data it can be seen that boiling 
PHCS in 2-mercaptoethanol has no effect on the 
reactivity of mAbs, when compared to an unaltered 
sandwich ELISA (fig 5.22). However, when the enzyme 
is boiled in SDS, or SDS PAGE sample buffer, the 
eventual reactivities of all mAbs are seen to increase 
substantially when compared to the unaltered sandwich 
ELISA.
Further consideration of these results 
suggested the need for a series of controls in 
which antibody-coated EIA plates were treated 
with SDS or SDS + 2-mercaptoethanol in the absence 
of PHCS. However, these experiments could not 
be completed since the MAb reagents were no longer 
available. It is unlikely that the differences 
in reactivity shown in Fig 5.22 are due to increased 
nonspecific binding of MAb to rabbit anti-PHCS; 
altered antigenicity of PHCS following exposure 
to SDS remains the most likely explanation of 
these results (see p 132).
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Fig.5.22 Histograms showing the relative activities 
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The activity of each mAb (at a concentration of
100ngml ) is expressed as the A4Q5 value reached
following a 30min incubation with substrate. A control
1
normal mouse serum (Z) was used at a dilution of Y q q • 
The pre-treatments of PHCS,1-4 are as described in 
the text (section 5.5).
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5.6 Discussion
In solid-phase immunoassays, antigen presentation 
plays an important role in the reactivity of mAbs. 
Solid-phase systems such as ELISAs and immunodot-blot 
assays are widely used in the screening of mAbs 
(Engvall, 1980; Hawkes et al, 1982; DeBlas and Cherwinski, 
1983). However, variation in the reactivity of mAbs 
has been noted between different ELISAs and liquid- 
phase assay systems (Al Moudallal et al, 1984;
McCullough et al, 1985). It has been suggested that 
some antibodies selected by direct ELISA are specific 
for antigenic sites which are hidden in the native 
protein, but become exposed once the protein is coated 
onto a solid support (Friguet et al, 1984) .
I have attempted to choose a method which 
ensures that mAbs are not lost due to failure to 
detect certain specificities in the initial screen.
For this reason, I have compared 12 assay systems 
for their ability to detect the members of a library 
of mAbs prepared against PHCS.
In ELISA systems using a poly-L-aspartate 
spacer (assays IV and V ) , the antigen is probably 
immobilized via free carboxylic acid groups on the 
spacer. When the anti-PHCS mAbs were compared, the 
results obtained in these assays were similar to those 
from assays were no spacer was used (assays I, II 
and III). This suggests that the interactions responsible 
for antigen immobilization are similar in these assays.
However, when the mAbs were compared using ELISA
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systems with poly-L-lysine as spacer (assays VI and VII) 
the results differed from those of assays I-V, thus 
indicating that the antigen is bound in a different 
orientation, or with an altered conformation, when 
using spacers carrying positive or negative charges 
(poly-L-lysine or poly-L-aspartate). This observation 
was confirmed when assays V and VII were used in the 
initial screening of colonies from a new fusion (table 
5.1). The use of the alternative spacers resulted 
in the detection of different sets of antibody-producing 
cultures.
In the sandwich ELISA (assay VIII), antigen 
is immobilized to a polyclonal antibody-coated solid 
phase. The results from this assay suggest that antigen 
presentation is quite different to that obtained in 
direct ELISAs. The fact that only in assay VIII were 
all the mAbs detected strongly indicates that in this 
system antigen is presented in a variety of orientations 
or conformations, as might be expected from the variety 
of specificities of anti-PHCS present in a polyclonal 
antibody preparation.
Comparison of mAbs using immunodot-blot- 
assays (IX, X and XI) showed some differences from 
the ELISA results. These can be attributed to 
differences in the mechanism of antigen immobilization 
between the two systems. Protein binding to 
nitrocellulose is thought to involve hydrophobic 
interactions predominantly, while binding to polystyrene 
is thought to involve ionic interactions. The sandwich 
dot assay (XII) gave positive results with all mAbs.
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This finding is similar to the sandwich ELISA result 
and presumably reflects similarities in the mechanism 
of antigen immobilization in these two systems, although 
the sandwich ELISA is more sensitive.
PHCS with bound oxaloacetate has been shown 
to exist in a 'closed' form, whereas the free enzyme 
exists in an 'open' conformation (Wiegand et al, 1984; 
Chothia and Lesk, 1985). The two sandwich ELISAs used 
in section 5.4 were designed to capture and present 
PHCS in its 'open' and 'closed' forms respectively.
MAb E was able to react well in both ELISA systems.
This may indicate that its binding site on the enzyme 
is altered very little between the 'open' and 'closed' 
forms of the enzyme. Conversely, the binding of the 
remaining mAbs was greatly reduced when the enzyme 
was presented in the 'closed' form, that is, with 
oxaloacetate bound. This suggests that the conformations 
of the binding sites of these mAbs may be substantially 
altered as the enzyme changes from an 'open' to a 
'closed' form, or that oxaloacetate blocks the 
recognition of the Abs for the epitope.
SDS is a detergent and protein denaturing 
agent. In the sandwich ELISAs in which the PHCS was 
boiled in SDS prior to its immobilization to a 
polyclonal antibody-coated solid phase, the reactivity 
of all the mAbs tested was increased. This may be 
due to the SDS denaturing the PHCS and freeing epitopes 
for second antibody binding, or by its increasing 
the ability of PHCS to bind polyclonal serum coated
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solid supports, thus increasing the epitope density 
presented.
This work emphasizes the importance of 
antigen presentation effects in solid phase ELISA, 
and immunodot-blot assays. The results show that 
sandwich assays, in which the antigen is immobilized 
in a variety of orientations using polyclonal antibodies, 
are capable of detecting mAbs with a wide range of 
specificities. This is in contrast to direct systems, 
whether a spacer is used or not, each of which detect 
a set of mAbs of more restricted specificity. This 
work suggests that sandwich assays should be used 
in preference to direct assays for initial screening 
to produce a library of mAbs with a wide range of 
possible specificities. Further, the work of using 
SDS, and oxaloacetate, to alter the form of the antigen 
presented by sandwich ELISAs emphasizes the importance 
of antigen presentation.
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CHAPTER SIX Peptide mapping of mAbs
6.1 Limited proteolysis of PHCS using chymotrypsin, 
trypsin and subtilisin.
6.2 Peptide mapping of mAbs to proteolytic fragments 
of PHCS.
6.3 Further peptide mapping of mAbs to a tryptic 
digest of PHCS.
6.4 Cleavage of asp-pro bonds by dilute acid.
6.5 Peptide mapping of mAbs to acid cleaved fragments 
of PHCS.
6.6 MAb immunoabsorbent chromatography performed 
on PHCS fragmented at asp-pro bonds.
6.7 Prediction of the products formed by cleavage 
of PHCS at asp-pro bonds.














6.1 Limited proteolysis of PHCS using chymotrypsin 
trypsin and subtilisin
Limited proteolysis of PHCS was performed 
as described in section 3.30. For each of the three 
proteolytic enzymes used, an initial time course 
digest was performed. Proteolysis was performed for 
10s, 2 min, 5 min, 10 min, 30 min and 2h, after which 
the reactions were stopped and the digests were run 
on 8-12% gradient SDS PAGE using the Laemmli method 
(section 3.23i).
a) Chymotrypsin: The results of a time 
course digest using a PHCS (subunit): chymotrypsin 
ratio of 500:1 are shown in fig 6.1. The molecular 
weights of the fragments were read from a graph of 
l°gi0%T versus log^gMwt plotted for the standards 
used in track 7. Log^g%T was calculated from the 
formula:
l°gi0%T = log^Q((DxAl%) + initial gel conc.)
where D is the distance travelled through the gel
and A1% = change in gel concentration
gel length
From fig 6.1 it can be seen that following 
a 10s proteolysis the PHCS subunit is the major band 
(49K), but feint bands are also present corresponding 
to molecular weights of 38.5K, 36K and 34K. At 5 min 
the 34K band has intensified greatly and new bands 
are visible at 32K, 30K and two bands (<20K). By 30 min
the 34K band is the major product, and the native
136
Fig 6.1 Time dependent proteolysis of PHCS by
chymotrypsin and subtilisin, shown on an 
8-12% gradient SDS PAGE gel
1 2 3 4 5 6 7 8 9 10 11 12
Tracks 1-6, PHCS fragments produced by limited proteolysis 
using chymotrypsin.
Track 7 Molecular weight markers: B-galactosidase(116K), 
BSA (66K), ovalbumin (45K), glyceraldehyde-3-phosphate 
dehydrogenase (36K), carbonic anhydrase (29K) and 
trypsin inhibitor (20K).
Tracks 8-13 PHCS fragments produced by limited 
proteolysis using subtilisin.
Time course. 10s (tracks 1 and 8), 2 min (tracks 
2 and 9), 5 min (tracks 3 and 10), 10 min (tracks 4 and 
11), 30 min (tracks 5 and 12), 2h (track 6).
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subunit (49K) has nearly all been degraded. Following 
2h PHCS is degraded to smaller molecular weight 
fragments.
b) Subtilisin: The results of a limited 
time course digest using a PHCS (subunit):subtilisin 
ratio of 500:1 are shown in fig 6.1. From these results 
it can be seen that following 5 min proteolysis the 
PHCS subunit (49K) is the major band, but feint products 
are seen with molecular weights of 42.5K, 40K, 34K
and 32K. From the results of the 30 min digest
(track 12) . it can be seen that the primary
cleavage product is of molecular weight 34K, with 
a major secondary product at 32K. One feint band 
(<20K) is also apparent in 30 min ' digests.
c) Trypsin: The results of a limited time 
course digest using a PHCS (subunit):trypsin ratio 
of 100:1 are shown in fig 6.2. From these results 
it can be seen that following 2 min proteolysis,
PHCS (49K) is cleaved to fragments of molecular weights 
34K, 32.5K, 27K and 26K. After 30 min of digestion 
the native subunit (49K) and the band at 34K have 
disappeared leaving only major bands at 32.5K and 
26K. Following 2h digestion the PHCS was digested 
to much smaller molecular weight products.
6.2 Peptide mapping of mAbs to proteolytic fragments 
of PHCS
Proteolysis of PHCS was repeated as in
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Fig 6.2 Time dependent proteolysis of PHCS by trypsin 
shown on an 8-12% gradient SDS PAGE gel
1 2 3 4 5 6 7 8
Tracks 1-6 PHCS fragments produced by limited 
proteolysis using trypsin: Time course: 10s (track 1) , 
2 min (track 2), 5 min (track 3), 10 min (track 4),
30 min (track 5), 2h (track 6).
Track 7. Undigested PHCS
Track 8 Molecular weight markers (as for fig 6.1).
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section 6.1, but single digestion times were chosen 
which gave the primary cleavage products found by 
Bloxham et al, 1982. Proteolysis was performed using 
chymotrypsin for 10 min, subtilisin for 45 min, or 
trypsin for 20 min. Following proteolysis, samples 
were run on 8-12% Laemmli SDS PAGE gels. Electrophoretic 
transfer of proteins from PAGE gels to nitrocellulose 
was performed essentially as in section 3.25, except 
that the transfer buffer was 25mM phosphate buffer, 
pH6.5, and transfer was carried out at 10V/0.24A for 
16h. Immunoblotting of nitrocellulose-bound fragments 
of PHCS was performed as in section 3.29, using mAbs 
B and C, and mouse anti-PHCS serum diluted 1/100 in 
1% casein/PBS.
For each experiment performed, 3 gel tracks, 
(molecular weight markers, undigested PHCS and fragmented 
PHCS, respectively) were stained, as described in section 
3.27, but were not transferred to nitrocellulose. 3 
similar tracks following transfer to nitrocellulose 
were stained with amido black, but were not immunoblotted. 
In this way it was shown that all the fragments of 
PHCS produced by chymotrypsin, trypsin and subtilisin, 
with molecular weights above 27K but not below this, 
were successfully transferred to nitrocellulose.
Similarly, it was shown that mouse anti-PHCS serum 
was reactive with all the bands transferred to 
nitrocellulose.
Results from the immunoblotting of proteolytic 
fragments of PHCS with mAbs B, C and mouse anti-PHCS 
serum are shown in figs 6.3 and 6.4.
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Fig. 6.3 Proteolytic fragments of PHCS after
immunoblotting with mAbs B,C and mouse anti-PHCS serum
1 2 3 4 5 6 7 8 9
Tracks 1-3;PHCS fragments following proteolysis by 
chymotrypsin
Tracks 4-6;PHCS fragments following proteolysis by 
trypsin
Tracks 7-9;PHCS fragments following proteolysis by 
subtilisin
Tracks 1,4and 7;pattern shown following immunoblotting 
with anti-PHCS serum
Tracks 2,5and 8;pattern shown following immunoblotting 
with mAb B
Tracks 3,6and 9;pattern shown following immunoblotting 
with mAb c
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Fig. 6.4 Proteolytic fragments of PHCS after
iinmunoblotting with mAb B
1 2  3 4
Track 1; undigested PHCS
Track 2; PHCS following proteolysis by chymotrypsin
Track 3; PHCS following proteolysis by trypsin
Track 4; PHCS following proteolysis by subtilisin
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These results show that the major proteolytic 
fragments of PHCS, generated by a 10 min digestion 
with chymotrypsin, have molecular weights of 36K, 34K 
and 31K. Trypsin (20 min digest) produced major fragments 
of 34K,33K and 31K, and subtilisin (45 min digest) 
gave strong bands of 39K, 33K and 31K.
The two mAbs (B and C) and the polyclonal 
anti-PHCS serum show strong reactivity with all these 
major bands. ,
6.3 Further peptide mapping of mAbs to a tryptic 
digest of PHCS
Proteolysis using trypsin was performed as 
in section 3.30, and samples prepared for SDS PAGE 
as in section 3.24. PAGE was performed using an 8-25% 
gradient gel in the Tris/Bicine system (section 3.23ii).
As in section 6.2, 3 gel tracks (molecular weight markers, 
undigested PHCS and fragmented PHCS, respectively) 
were stained using coomassie blue, and the remaining 
tracks were transferred to nitrocellulose by the method 
described in section 3.25. Following transfer, 3 tracks 
(molecular weight markers, undigested PHCS and fragmented 
PHCS, respectively) were stained with amido black by 
the method described in section 3.28. The remaining 
tracks were immunoblotted (method 3.29) with mAbs B,
C and E, normal mouse serum diluted 1/100 and mouse 
anti-PHCS serum diluted 1/100. For mAb E, 4%(w/v) PEG 
was included to aid complex formation during its 
incubation with a nitrocellulose strip containing digest
bands.
A graph of log^g%T versus logMWt was plotted 
for the molecular weight standards, with data obtained 
from the stained gel (fig 6.5).
L°gio%T values were calculated from the 
distances travelled throughout the gel, for each fragment 
produced following proteolysis, and the corresponding 
molecular weights were read off the graph (fig 6.5).
These results are summarized in table 6.1. The intensity 
of staining of each band in the gel by coomassie blue, 
as a measure of protein quantity, wasvisually rated 
on a scale of 1-6. The most intense band was assigned 
a value of 6 and the least intense a value of 1. These 
data are included in table 6.1.
The reactivities of antibodies following 
immunoblotting of PHCS fragments is shown in fig 6.6 
and a summary of the reactivity of antibodies with 
fragments is included in table 6.1.
These results show that the major proteolytic 
fragments of PHCS, after a 20 min digestion by trypsin, 
have molecular weights of 40K, 33.0-35-5K, 23.5K, 13.5K 
and 9.5K. Polyclonal anti-PHCS serum shows a strong 
reactivity towards all these major bands except that 
of molecular weight 13.5K. MAbs B and C show reactivity 
with major bands at 40.OK, 33.0-35.5K and 9.5K, but 
not with bands at 23.5K or 13.5K. MAb E shows reactivity 
with major bands at 40.OK, 33.0-35.5K and 23.5K.
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Fig 6.5 Graph of log^gMWt versus log%T drawn for the 








Table 6.1 Summary of the reactivity of the mAbs with 
tryptic fragments of PHCS
Fragment MWt (K) Band
Intensity
Reactivity of Antibodies
mAbB mAbC ! mAbE anti-PHCS
serum
a 49.0 3 + + + +
b 40.0 3 + + + +
c 37.5 2 + + - +
d 33.0-35.5 6 + + + +
e 32.5 2 7 7 - 7
f 33.5 1 - - - -
g 28.0 1 - - - -
h 27.0 1 - - - -
i 25.5 2 - - - +
j 24.0 2 - - - +
k 23.5 5 - - + +
1 22.5 1 - - - +
m 21.0 2 ? + - +
n 20.0 1 - - - -
o 19.0 1 + + - +
P 18.0 2 - - - +
q 16.0 1 - - - -
r 14.5 2 - - - -
s 13.5 4 - - - -
t 11.0-12.5 1 - - - -
u 9.5 3 + + - +
V 8.5 1 - - - -
w 7.5 1 - - - -
X 6.5 1 - - - -
Y 5.5 1 - - - -
The intensity of the bands were assigned according to 
section 6.3.
Reactivity of antibodies is assigned on a positive (+) 
or negative (-) basis. Where a ? is assigned, the 
reactivity was uncertain.
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Fig.6.6a 20 min proteolysis of PHCS by trypsin shown on 
an 8-20% gradient PAGE gel
1 2  3 4
Track 1; undigested PHCS
Track 2; standards: 66K,45K,36K,29K,and 20K,(as per 
fig. 6.1),plus lactalbumin ( 14.2K)
Track 3; PHCS fragments produced following proteolysis 
by trypsin for 20 min 
Track 4; standards: myoglobin (17K),myoglobin I+II (14.4K), 
myo. I (8.2K),myo. II (6.2K),and myo. Ill (2.5K)
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Fig 6.6b Tryptic fragments of PHCS after immunoblotting
with mAbs B,C, and mouse anti-PHCS serum
1 2 3 4 5 6 7 8
Tracks 1,2and 3; amido black staining of protein 
following electrophoretic transfer to 
nitrocellulose 
Track 4; immunoblot pattern shown by anti-PHCS serum 
Track 5; immunoblot pattern shown by mAb B
Track 6; immunoblot pattern shown by mAb C
Track 7; immunoblot pattern shown by mAb E
Track 8; immunoblot pattern shown by normal serum
Track 1; standards as per track 4,fig.6.6a 
Track 2; standards as per track 2,fig.6.6a 
Tracks 3-8; PHCS fragments following proteolysis by 
trypsin
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6.4 Cleavage of asp-pro bonds by dilute acid
Cleavage of PHCS at asp-pro bonds was performed 
as described in section 3.31. Initially, a time course 
was performed covering the times 10 min, 20 min,
30 min, lh, 2h and 4h. The products were run on a 
8-20% Laemmli PAGE gel which included 6M Urea (fig 6.7). 
From tracks 2-9, it can be seen that the digest 
progresses with time over a period of up to 4h. After 
10 min and 20 min, larger molecular weight fragments 
(>27K) predominate. As the reaction proceeds, up 
to 4h, only small molecular weight fragments (<17K) 
remain. Two time points were chosen for future use, 
a 30 min digest and a 90 min digest. From fig 6.7 
it can be seen that these two times cover the whole 
range of fragments produced.
6.5 Peptide mapping of mAbs to acid cleaved fragments 
of PHCS
PHCS was cleaved at asp-pro bonds for 30 
min and 90 min as described in section 3.31. The 
products were run on an 8-25% tris-bicine gel by 
the method described in section 3.23ii. Electrophoretic 
transfer of fragments to nitrocellulose, and 
immunoblotting, were performed as described in section 
3.25 and 3.29.
A graph of log^g%T versus log MWt (fig 6.8) 
was plotted for the molecular weight markers, with 
data obtained from the gel (fig 6.9). Figure 6.8 
also shows that it was possible to transfer to
\
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Fig.6.7 Time dependent cleavage of PHCS at asp-pro 
bonds by dilute acid,shown on an 8-20%,6M urea, 
Laemmli PAGE gel
1 2 3  4 5 6 7  8 9  10 11
Track'll ; undigested PHCS
TracklO; standards:116K,66K,45K,36K,29K,20K,17K,14.4K,
8. 2K,and 6.2K
Tracks ^-3; Time course mild acid digest of PHCS (10 sec, 
10 min,20 min,30 min,1h ,2h,and 4h respectively) 
Track 2.; standards:116K,66K,4 5K,36K,29K,and 20K 
Track 1; standards:17K,14.4K,8.2K,and 6.2K
The molecular weight standards used were the same 




Fig 6.8 Graph of log^gMWi versus log%T drawn for 









Fig 6.9 8-25% SDS PAGE gel, and nitrocellulose sheet,
showing PHCS fragments cleaved at asp-pro bonds
Tracks 1-5 SDS PAGE performed as per text 6.5.
Tracks 6-7 nitrocellulose following protein transfer, 
performed as per text 6.5.
Track 1 undigested PHCS
Tracks 2 and 6 molecular weight standards? myoglobin 
(17K), myoglobin I and II (14.4K), myo I (8.2K), myo II 
(6.2K), myo III (2.5K)
Tracks 3 and 9 90 min cleavage at asp-pro bonds
Tracks 4 and 7 molecular weight standards; BSA (66K),
ovalbumin (45K), glyc-3-P-DH (36K), carbonic anhydrase 
(29K), trypsin inhibitor (20K), lactalbumin (14.2K).
Tracks 5 and 8 30 min cleavage at asp-pro bonds
12 3 4 5 6 7  8 9
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nitrocellulose all bands following digestion. The 
results from the immunoblots performed, using mAbs 
B and C, normal mouse serum and mouse anti-PHCS serum 
are shown in fig 6.10. The data are summarized in 
table 6.2. The intensity of staining of each band 
in the gel by coomassie blue, as a measure of protein 
quantity, was visually rated on a scale of 1-6, the 
most intense band being assigned a value of 6, and 
the least intense a value of 1.
These results show the reactivity of mAbs 
B and C with acid cleaved PHCS are identical. Both 
mAbs react with products of molecular weights 6.5K- 
8.5K, 13.5K, 21.OK, 23.5K, 27.0K-27.5K, 33.5K, 33.5K- 
36.OK and 37.OK.
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Fig 6.10 PHCS fragmented at asp-pro bonds,after 
immunoblotting with mAbs B,and C,normal mouse serum, 
and anti-PHCS serum
1 2 3 4 5 6 7 8 9101112
Tracks 1-4; amido black staining of protein following 
electrophoretic transfer to nitrocellulose 
Track 1; standards: 17K,14.4K,8.2K,6.2K,and 2.5K,(as 
per fig. 6.6a)
Track 2; standards: 66K,45K,36K,29K,20K,and 14.2K,(as 
per fig. 6.6a)
Tracks 3,5,7,9,and 11; 30 min mild acid hydrolysate 
of PHCS
Tracks 4,6,8,10,and 12; 9 0 min mild acid hydrolysate 
of PHCS
Immunoblots performed with mAb B(tracks 5 and 6), 
mAb C (tracks 7 and 8), anti-PHCS serum (tracks 9 
and 10 ) ,and normal mouse serum (tracks 11 and 12)
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Table 6.2 Summary of the reactivity of mAbs with PHCS 
fragments, produced by mild acid hydrolysis, 
defined by immunoblotting















a 49.0 4 _ + + +
b 38.5-40.0 4 - - - -
c 37.0 3 - ? + +
d 33.5-36.0 5 - + + +
e 33.5 1 - + + +
f 29.5 1 - - - -
g 27.0-27.5 4 - + + +
h 26.0 4 - ? +
i 23.5 3 - + + +
j 22.0 3 3 - T +
k 21.0 3 - + + +
1 19.5 3 - - - -
m 17.5 - 1 - -
n 15.5 1 2 - - +
o 15.0 1 3 - - -
P 13.5 1 - + + +
q 11.5-12.5 5 5 - - +
r 10.0-11.0 5 5 - - -
s 9.0 - 2 - - -
t 6.5-8.5 5 6 + + +
u 5.0 1 3 - - -
V 3.0-6.0 - 4 - - -
The intensity of the bands were assigned according to 
section 6.3.
Reactivity of antibodies is assigned on a positive (+), 
or negative (-) basis. Where a ? is assigned, the 
reactivity was uncertain.
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6.6 MAb immunosorbent chromatography performed on PHCS 
fragmented at asp-pro bonds
MAbs B and C were separately coupled to 
Sepharose 4B by the method described in section 3.32. 
With mAb B a coupling efficiency of 51% was achieved, 
leading to the production of a 1.5ml column with 2.55mg 
of coupled mAb. With mAb C a coupling efficiency of 
60% was achieved leading to the production of a 1.5ml 
column with 3.00mg of coupled mAb.
Both columns were loaded with 300pig of PHCS 
hydrolysed (at asp-pro bonds) by treatment with mild 
acid for 90 min. MAb immunosorbent chromatography 
was performed as described in section 3.33. The bound 
peptides were eluted with 0.5M NH^OH, pH10.8, freeze 
dried and run on 8-25% tris-bicine PAGE gels as 
described in section 3.23ii. The band patterns obtained 
from both the mAb B and mAb C columns were identical 
and an example is shown in fig 6.11. The resultant 
calibration curve for molecular weight markers is 
shown in fig 6.12. The results are summarized in 
table 6.3.
These results show that mAbs B and C are 
highly reactive with a 6.5-8.OK molecular weight 
fragment produced by acid hydrolysis of PHCS. A very 
weak reactivity may also be observed with a 13.OK 
molecular weight product.
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Fig 6.11 8-25% SDS PAGE gel showing a 90 min mild acid 
hydrolysis of PHCS, and the fractions retained by the 
mAb C immunoaffinity column
■
-
1 2 3 4 5 6 7
Tracks 1,3 and 5. low molecular weight standards; myoglobin 
(17K), myoglobin I+II (14.4K), myo I (8.2K), myo II 
(6.2K) and myo III (2.5K)
Track 2. 90 min mild acid hydrolysis of PHCS
Track 4. The fraction of a 90 min mild hydrolysis of
PHCS retained by mAb C immunoaffinity column.
Track 6. High molecular weight markers; as track 4,fig 6.9 
Track 7. Undigested PHCS
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Fig 6.12 Graph of log^gMWt versus log%T drawn for the 









Table 6.3 Summary of the reactivity of mAbs with PHCS 
fragments produced by mild acid hydrolysis, 
defined by immunosorbent chromatography




j 22.5 3 — —
k 21.0 1 - -
m 18.0 1 - -
n 16.5 1 - -
o 16.0 3 - -
q 12.0-13.0 6 + +
r 10.0-10.5 4 - -
s 9.0 3 - -
t
o•001in* 6 + + + + + +
u, V 3.5-5.5 4 - -
Results were from fig 6.11.
The intensity of staining of each band in the 90 min 
digest track were rated on a scale of 1-6. The most 
intense being assigned a value of 6, the least intense 
a value of 1.
Fragments' were named according to their corresponding 
name in table 6.2.
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6.7 Prediction of the products formed by cleavage 
of PHCS at asp-pro bonds
From the amino acid sequence of PHCS, fig 
3, page 43, it can be seen that 4 asp-pro bonds occur. 
Using the known molecular weights of amino acids, 
the expected molecular weight of each product of a 
cleavage at asp-pro bonds was calculated. A complete 
and specific hydrolysis at asp-pro bonds would yield 
5 products containing residues 1-59, 60-257, 258-327, 
328-344 and 345-437. The expected products of a limited 
hydrolysis are shown in table 6.4.
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Table 6.4 Theoretical products formed by cleavage of 
PHCS at asp-pro bonds
Molecular weights of fragments containing amino acids
1-59 60-257 258-327 328-344 345-437
48969 48969 48969 48969 48969
38500 42500 42500 42500 42500
36400 38500 38500 38500 20300
28700 36400 36400 32000 12600






6.8 Peptide mapping of mAbs to PHCS fragmented at 
asn-gly bonds
PHCS was cleaved at asn-gly bonds with 
hydroxylamine as described in section 3.31. The products 
were run on an 8-25% tris-bicine gel by the method 
described in section 3.23ii. Electrophoretic transfer 
of fragments to nitrocellulose and immunoblotting 
were performed as described in sections 3.25 and 3.29.
A graph of log^g%T versus logMWt was plotted 
for the molecular weight markers. Only 3 bands were 
observed from a track of the digest; one corresponded 
to the native PHCS (49K), the remaining two bands 
had molecular weights of 27K and 18.5K. All three 
bands transferred well to nitrocellulose, and are 
shown in track 1 fig 6.13. From fig 6.13 it can be 
seen that mAbs B and C, and mouse anti-PHCS serum 
react with each of the three bands found following 
fragmentation of PHCS by hydroxylamine. Normal mouse 
serum shows no reactivity.
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Fig 6.13 Immunoblots of PHCS fragmented at asn-gly 
bonds by hydroxylamine
1 2 3456 7
Tracks 1-7; PHCS fragmented at asn-gly bonds as described 
in section 6 .8 , following transfer to nitrocellulose strips 
Track 1? Resultant staining by amido black.
Track 2; Immunoblotting pattern given by mAb B
Track 3; Immunoblotting pattern given by mAb C
Tracks 4, 5; Immunoblotting pattern given by normal mouse
serum




Initial experiments to effect the 
electrophoretic separation of peptide fragments 
involved SDS PAGE usincr the Laemmli system (section
6.1 and 6.2). It was found however that this did not 
give the required resolution of small fragments 
(1K-10K), even when larger gradients of 8-20% or 
8-25% acrylamide were used. Adaptations were made 
similar to those of Hashimoto et al, 1983, in which 
the acrylamideibisacrylamide ratio was changed from 
37:1 in the Laemmli system to 20:1. This change did 
create a better resolution of the smaller molecular 
weight fragments. Inclusion of 6M urea in the gel 
system, however, appeared to be of no advantage.
The system finally adopted for use was a 
modification of the Tris-bicine system of Johnstone 
and Thorpe, 1982ppl59-161, in which the acrylamide: 
bisacrylamide ratio was changed to 20:1. It can be 
seen from fig 6 . 6 that molecular weight bands from 
2K to 66K are well defined, and fig 6.5 shows that 
molecular weight determinations within this range 
are readily performed.
The electrophoretic transfer of proteins 
from PAGE gels to nitrocellulose seemed to vary 
greatly in efficiency with the buffer used to perform 
it. 25mM phosphate buffer, pH6.5 was found to give 
a more efficient transfer than did 15.6mM Tris- 
120mM glycine, pH8.3, which is a popular transfer 
buffer, Gershoni and Palade, 1982. Both of these
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buffers however gave very poor transfer of fragments 
with molecular weicrhts between 2K and 20K, for both 
short (2h) and long (16h) transfer times. Passive 
transfer of proteins performed according to method 
3.26 gave very good transfer (>50% after 36H); however, 
small molecular weight fragments had a tendency to 
diffuse laterally, so reducing the definition of bands 
obtained in PAGE.
The use of 2mM sodium acetate/5mM MOPS,
20% ethanol, pH7.5 in a transfer for 2h gave approximately 
90% transfer of proteins in the molecular weight range 
2K-20K, and approximately 70% transfer in the molecular 
weight range 20K-66K.
Previous studies of the proteolysis of PHCS 
by trypsin, chymotrypsin and subtilisin have shown 
that two predominant primarv fragments are produced.
The larger fragments, with molecular weights of 35K- 
38.5K, were shown to contain the amino terminal sequence 
of the native PHCS, while the small fragments, 9K-12K, 
were shown to contain the carboxy terminus (Wiegand,
1979, Bloxham, 1980). The primary cleavage sites of 
these proteolytic enzymes on PHCS have been established 
by Bloxham et ad, 1981,1982. Further work by Lill 
et al, 1984, on the primary actions of these proteases 
on PHCS has verified these cleavage sites, which are 
summarized in table 6.5.
The proteolytic digest patterns shown in 
figs 6.1, 6.3 and 6.4 for chymotrypsin and subtilisin 
agree well with the data in table 6.5. The immunoblot
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Table 6.5 Limited proteolysis of PHCS
Primary cleavage sites, determined by amino terminal 
sequence analysis (Lill et al, 1984; Bloxham et al, 












Chymotrypsin Leu-Arg 1-323 36K
(323-324) 324-437 13K
Subtilisin Ala-Leu 1-321 35.5K
(321-322) 321-437 13. 5K
Val-Leu 1-322 36K
(322-323) 323-437 13K





patterns observed show that mAbs B and C are reactive 
against the large 33-34K molecular weight bands of 
these digests. It is concluded from this that mAbs 
B and C bind to an epitope found between residues 
1-321 of the native PHCS.
The proteolytic digest patterns shown in 
figs 6.2, 6.3 and 6.4 for trypsin agree well with 
the data in table 6.5. The immunoblot patterns 
observed show that mAbs B and C are reactive against 
the large 33-34K molecular weight bands of this digest. 
It is concluded from these data that mAbs B and C 
bind to an epitope found between residues 1-313 of 
the native PHCS.
However, due to the poor transfer of low 
molecular weight fragments these experiments do not 
prove that the mAbs cannot also bind to residues 
between 313-437 of PHCS.
In the further mapping studies performed 
in section 6.3, low molecular weight fragments were 
resolved well in PAGE, and transfer was very good 
to nitrocellulose. Using the Tris/bicine gel system, 
which gave the best resolution of small molecular 
weight bands, the primary fragments as per table 6.5, 
are well defined. For a cleavage at residues 313-314, 
the products at 33-35.5K, and 13K or 14.5K can be 
clearly seen. From the immunoblot results it is seen 
that mAbs B and C react well with the larger fragment, 
corresponding to residues 1-313. They show no reactivity 
however to the smaller fragment corresponding to
1 6 6
residues 313-437.
Lill et al, 1984, showed that for limited 
trypsinolysis the ratio of cleavage at residues 313-314 
is twice that seen at residues 366-367. This explains 
the greater intensity of the product band at 33-35.5K 
over that seen at 40K. The small molecular fragment 
produced from a cleavage at 313-314 (14K) is less 
intense than its larger partner (33-35.5K), due to 
the likelihood of its also being cleaved at 366-367, 
producing further small products.
In this tryptic digest of PHCS a further 
major product is seen at 23.5K. Due to its intensity, 
and the fact that major primary cleavage sites are 
at 313-314 and 366-367, it must lie within the sequence 
1-313. The immunoblotting data show that although 
the epitopes of mAbs B and C lie within the region 
1-313 thev are not present in this 23.5K subdivision 
of this region, but are however present in a 9.5K 
subdivision. Again due to its intensity the 9.5K 
fragment must lie within residues 1-313.
In a similar fashion it is seen that mAb E 
reacts with the major 33-35.5K product of a cleavage 
at 313-314, but does not react with the smaller 
13.5 or 14.5 product of it. Therefore its epitope 
lies within the region 1-313. However mAb E reacts 
with the 23.5K cleavage product but not with the 9.5K 
product.
Peptide mapping studies, explained later, 
following cleavage of PHCS at asp-pro bonds, together 
with work performed using a synthetic peptide has
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resolved the epitopes of mAbs B and C to lie within 
the region 258-313. This indicates that this region 
must be present on the 9.5K fragment, as mAbs B and 
C react with it.
Assuming that during the 20 min proteolysis, 
trypsin has been specific, with its cleavage sites 
being either at lysine or arginine, then only two 
sites of cleavage lie within the region 1-313 such 
that these two sized fragments can be produced and such 
that the 9.5K fragment contains the epitope present 
for mAbs B and C. These sites are lys-leu (206-207) 
and Arg-leu (229-230). This suggests that mAb E must 
bind to an epitope present within residues 1-230.
Future verification of this may be performed by 
sequencing the fragments.
The data also show that mouse anti-PHCS 
serum does not react with the 13.5K or 14.5K fragment. 
This indicates that following immunization with the 
native antiqen, antibodies are not readily produced 
to the regions of the protein between residues 
314-437.
Previous studies have demonstrated that 
under acidic conditions asp-pro peptide bonds are 
cleaved more rapidly than any other peptide bonds 
normally present in proteins (Piszkiewicz, 1970).
The present study uses the method of Rittenhouse and 
Marcus, 1984, to perform peptide mapping of PHCS 
following cleavage at asp-pro peptide bonds. Table
6.4 shows the molecular weights of the expected products 
of a limited acid hydrolvsis of PHCS. Including the
1 6 8
native enzyme a total of 15 fragments would be expected. 
Results from table 6.2 show that hydrolysis of PHCS 
by mild acid produces a total of 22 fragments, showing 
that some cleavage other than at asp-pro bonds has 
occurred. This cleavage is likely to occur at an 
asn-pro bond occurring at residues 369-370.
The immunoblots following trypsinolysis 
have shown that mAbs B and C bind to epitopes between 
residues 1-313. From table 6.4 it can be seen that 
the molecular weights of fragments corresponding to 
residues 328-344 and 345-437 are 2.IK and 10.5K 
respectively. Results summarized in tables 6.2 and
6.3 show that mAbs B and C are not reactive with 
fragments r and v corresponding to these molecular 
weights. This shows that mAbs B and C do not react 
with an epitope between 328-437, corroborating the 
results found following trypsinolysis.
Following mild acid hydrolysis, the major 
band (j) of molecular weight 22K corresponding to 
the expected molecular weight of the fragment containing 
residues 60-257 is not reactive with mAbs B and C.
For an epitope between these residues to be recognised 
no products below 22K should be reactive with mAbs 
B and C. However fragments of 21.OK, 13.5K and 6.5-8.5K 
are reactive with mAbs B and C. Thus the epitopes 
recognised by mAbs B and C must be present either 
between residues 1-59, or 258-327.
From table 6.3 it is seen that the molecular 
weights of fragments corresponding to residues 1-59
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and 258-327 are 6.5K and 7.7K respectively. From the 
fragments observed (tables 6.2 and 6.3) it is likely 
that fragment t (6.5K-8.5K) corresponds to the 7.7K 
fragment expected for residues 258-327, and fragment 
v (3.0K-6.0K) corresponds to the 6.5K fragment expected 
for residues 1-59. As mAbs B and C react with only 
one of these fragments (6.5K-8.5K) it seems likely 
that their epitopes lie between residues 258-327.
From table 6.4 it can be seen that only 4 fragments, 
excluding the native PHCS, are expected to contain 
residues 1-59, and only one of these (6.5K) has a 
molecular weight below 28K. However, table 6.2 shows 
that mAbs B and C react with fragments of molecular 
weights 27-27.5K, 23.5K, 21.OK, 13.5K and 6.5-8.5K.
From table 6.4 it can be seen that 8 fragments, 
excluding native PHCS, are expected to contain residues 
258-327, and 3 of these (20.3K, 9.8K and 7.7K) have 
molecular weights below 28K. This evidence also suggests 
that the epitopes recognised by mAbs B and C are 
between residues 258-327. Combining this with the 
results following trypsinolysis, the epitopes recognised 
by both mAbs B and C lie between residues 258-313.
Further work in our laboratory by Daham 
Ali has shown that mAbs B and C both recognise a 
synthetic peptide corresponding to residues 288-302, 
when assayed by direct ELISA. This work shows that 
the epitope recognised by both mAbs B and C does indeed 
lie between residues 288-302.
Following cleavage at asn-gly bonds (section 
6 .8 ), only 2 products were observed with molecular
170
weights of 28.OK and 18.5K. Only 1 asn-gly bond occurs 
in PHCS, at residues 267-268. The expected molecular 
weights of fragments produced following cleavage of 
this bond are 30K and 19K, correlating well with the 
observed products. The binding of mAbs to both fragments 
might suggest that part of the epitope exists in each 
fragment. This may mean that the epitopes recognised 
by mAbs B and C both contain part of the sequence 
between residues 258-267 plus part of the sequence 
288-302.
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This chapter describes the methods used to 
predict the antigenic sites present on PHCS. The 
rationale for the use of these methods has been discussed 
in sections 1.4-1.4.6 .
These studies have been performed by other 
workers in collaboration with our group, and alongside 
the experimental approach performed by myself.
7.2 Prediction of the epitopes of PHCS using 
hydrophilicity data
This procedure was first described by Hopp 
and Woods, 1981.
From the solvent parameters of Levitt, 1976, 
each of the 20 amino acids commonly found in proteins 
is assigned a hydrophilicity value. The values used 
are shown in table 7.1. A hydrophilicity profile is 
achieved by repetitively averaging these values for 
overlapping sets of 6 residues along the chain and 
plotting them versus the residue number of the leading 
residue.
The hydrophilicity profile for PHCS was 
performed by S.A. Garforth, 1985. In this work he 
adapted a program written in Hewlett-Packard BASIC, 
for use on a BBC micro-computer. The profile so obtained 
is shown in fig 7.1.
From the results shown in fig 7.1 it can 
be seen that the top five peaks of hydrophilicity 
occur at residues 297-302, 323-328, 293-299, 289-294
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* Based on the solvent parameter values of Levitt, 
1976.





and 82-87. It should however be noted that according 
to Hopp and Woods only the highest peak of hydrophilicity 
was invariably found to correlate with antigenic sites 
in the model protein systems they used. For PHCS the 
highest peak of hydrophilicity occurs between•residues 
297-302.
7.3 Prediction of the epitopes of PHCS using 'Composite 
Surface Profile1 data
This procedure was described by J.M.R. Parker
1986.
Each of the 20 amino acids commonly found 
in proteins was assigned a 'surface profile value'.
The 'surface profile' values were arbitrarily assigned 
on a scale of 0-100, and are a composite of HPLC 
hydrophilicity indices, accessibility and flexibility 
values, as described in section 1.4.5. A composite 
surface profile is achieved by repetitively averaging 
these values for overlapping sets of 7 residues along 
the chain, and plotting them versus the fourth residue 
number of each set of 7.
The composite surface profile for PHCS was 
performed by J.M.R. Parker, and is shown in fig 7.2.
From the results shown in fig 7.2, it can 
be seen that the top five peaks of composite surface 
profile occur at residues 236-246, 325-332, 78-90,
288-302 and 363-372. Parker, personal communication, 
































7.4 Prediction of the epitopes of PHCS using atomic 
mobility values
Use of X-ray crystallography gives not only 
the precise atomic coordinates, but also atomic 
temperature factors (B values). The temperature factor 
represents the mean-square displacement of each atom, 
and when plotted against residue number gives a graphic 
image of the degree of mobility existing along the 
polypeptide chain, as described in section 1.4.4.
The B-values obtained for the atoms in PHCS 
were determined by Remington et al, 1982. The mobility 
profile is shown in fig 7.3.
From the results shown in fig 7.3, it can 
be seen that three major peaks of mobility occur at 
residues 81-85, 285-302 and 1-5.
7.5 Prediction of the epitopes of PHCS using protrusion 
indices
This procedure was first proposed by Thornton 
et al, 1986 and has been described in section 1.4.2. 
Protrusion indices have been calculated for PHCS from 
its X-ray crystallographic atomic coordinates. These 
PI values are calculated values for each amino acid 
of the PHCS and are a measure of the extent to which 
a residue protrudes out from the surface of the 
molecule.
The data used were provided by Dr.J.M. Thornton 

























Fig 7.4 shows a protrusion index profile 
drawn by plotting the PI value of each amino acid 
against its residue number.
A further protrusion index profile was 
obtained by repetitively averaging PI values for 
overlapping sets of 6 residues along the chain and 
plotting them versus the residue number of the last 
residue in the set. This data is presented in fig 7.5.
From these data it can be seen that the 
most protrusive regions contain residues 421-437, 
119-137, 14-42, 287-313, 154-166 and 191-202.
7 . 6  Prediction of the surface residues of PHCS existing 
in continuous regions
This work was first described by Barlow 
et al, 1984.
The method used involves centering a sphere 
of radius 6? on each surface atom of the protein, and 
calculating the proportion (F) of the centres of other 
surface atoms enclosed by the sphere which belong 
to residues local in the amino acid sequence. Surface 
atoms were defined as those with contact areas >2 
Local surface atoms were defined as those ±3 residues 
distant in the sequence of the residues under 
consideration. Residues which contain no surface atoms 
were assigned a value of F=0.
The 'continuous surface' profile was performed 
by Dr. J.M. Thornton, 1986. These data are presented 
in fig 7.6. From these data, using a cut off at 50%
Fig 7.4 Protrusion index profile of PHCS

















Fig 7.5 Averaged protrusion index profile of PHCS
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Fig 7.6 Histogram of % continuous surface (F) for residues in PHCS
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'continuousness1, it was predicted that the most likely 
continuous antigenic sites would contain residues 
418-424, 201-206, 159-166, 129-136 and 25-35.
7.7 Discussion
In this chapter five different predictive 
approaches have been applied to compute the likely 
antigenic sites present on PHCS. All predictions were 
performed for the monomer of PHCS, with 437 residues. 
The first two approaches (hydrophilicity indices, 
and composite surface profile values), use empirical 
values for each amino acid which are then applied 
to the primary sequence data. The remaining approaches 
(mobility predictions, protrusion (indices) and 
continuous surface profile) rely on physical data 
obtained by X-ray crystallography.
The major antigenic sites predicted by each 
method are shown on table 7.2. Predictions made by 
methods 7.2, 7.3, 7.4 and 7.5 all suggest that a region 
contained within residues 288-302 is likely to be 
an antigenic site. Results from method 7.6 do not 
predict this region to contain a continuous epitope 
as residues 288, 290, 291, 292, 294, 298, 301 and 
302 show less than 50% 'continuousness'. Therefore 
an epitope is strongly predicted to occur between 
residues 288-302, but it is likely to be partly 
discontinuous. Two further discontinuous epitopes 
(residues 81-87 and 323-328) are predicted by methods
184
Table 7.2 Summary of the predicted epitopes of PHCS










(C) Mobility (1) 81-85
(2) 285-302
(3) 1-5












7.2, 7.3, 7.4 and methods 7.2, 7.3, respectively.
Methods 7.5 and 7.6 predict continuous antigenic sites 
to exist at residues 159-166, 129-136 and 25-35. Methods
7.5 and 7.6 were however performed on the monomeric 
subunit of PHCS, thus some of the sites predicted 




The first stage of this project(chapter 4) was 
the production of a library of 11 mAbs against PHCS. In 
this report the importance of multiple re-cloning of cells 
has been emphasized,to reduce the risk of overgrowth by 
non-antibody producing cells. In my work approximately 
4-5% of growing cells after fusion were found to secrete 
antibody reactive with the antigen used for immunisation. 
This agrees with the work of Goding,1980,whose fusion 
strategy was followed.
Of the mAbs raised 9 were classified as being of 
IgM type and 2 of being IgG type. This higher ratio of IgM 
to IgG secreting cells is generally reported in mAb work.
Investigation of a series of solid phase immuno­
assays (chapter 5) has shown how antigen presentation has 
a significant effect on the reactivity of mAbs. Of 12 
different direct and solid phase immunoassays tested,a 
sandwich ELISA proved to be the most useful for detecting 
all of a heterogeneous group of mAbs. The superiority of 
this assay over the other systems used is thought to be 
due to its ability to present simultaneously a soluble 
antigen in a variety of orientations or conformations.
This might be expected from the variety of specificities 
of anti-PHCS present in the coating polyvalent antibody 
preparation.
Sandwich ELISAs were developed in which the
187
antigen is presented in a 'closed' form(with oxaloacetate 
bound),and in an 'open' form (with no ligand present), 
see section 5.4. This work has shown that mAb E is able 
to bind equally well to PHCS in both its 'open' and 
'closed' forms. However mAbs B and C bind much less well 
to PHCS in the 'closed' form than to it in its 'open' 
form. Wiegand et al,1984,have shown that the conformation 
of the small domain (residues 275-380,fig.4),changes 
considerably between the different forms of the enzyme. 
However,the conformation of the large domain (residues 
1-274 and 381-437) is fairly constant in all forms of 
the enzyme. Thus the reactivity of mAbs with the two 
forms of the enzyme suggests that mAbs B and C react 
between residues 275-380,and mAb E reacts with an epitope 
present either between residues 1-274 or381-437.
Epitope mapping studies (chapter 6) performed 
on fragments of PHCS produced by enzymic and chemical 
cleavage have defined the regions recognised by mAbs B,
C and E. MAbs B and C recognise an epitope lying between 
residues 258-313,shown in fig.8.1,and mAb E recognises 
an epitope between residues 1-230. Further studies using 
a synthetic peptide have shown that mAbs B and C bind to 
epitopes between residues 288-302,shown in fig.8.2.
Thus the epitopes recognised by mAbs B and C are on an 
exposed surface loop of PHCS.
This experimentally determined epitope within 
residues 288-302 is predicted to be antigenic using
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Fig.8.1. Computer graphics image of PHCS highlighting 
the position of residues 253-313
This computer graphics image shows the backbone 
of the amino acid sequence of a monomer of PHCS. The 
position of residues 258-313 is highlighted in yellow,the 
remainder of the molecule being shown in blue.
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Fig.8.2. Computer graphics image of PHCS highlighting 
the position of residues 288-302
This computer graphics image shows the backbone 
of the amino acid sequence of a monomer of PHCS. The 
position of residues 288-302,in an exposed loop,is 
highlighted in yellow,the remainder of the molecule being 
shown in blue. The two arrows (in black) show the position 
at which binding occurs with the second monomer.
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hydrophilicity data (section 7.2),composite surface 
profile data (section 7.3),atomic mobility values 
(section 7.4),and protrusion indices (section 7.5).
This epitope is however predicted to be partly discon­
tinuous by a surface continuogram (section 7.6).
This work has successfully shown how the 
antigenic sites recognised by antibodies can be defined 
experimentally by:
a) Immunoassays designed to present an antigen 
in different set conformations.
and b) Epitope mapping studies performed on 
fragments of the antigen.
The simultaneous use of a predictive approach 
to determine antigenic sites has shown the value of 
four methods (sections 7.2-7.4) in their ability to 
predict epitopes.
In a continuation of this project,further 
experimental work is to be performed to delineate the 
epitopes recognised by mAbs A,D,E,F,G,H,K,Land M. These 
data will enable a more complete evaluation to be 
performed of the relative merits of the various methods 
discussed for antigenic site prediction.
MAbs B and C bind to an epitope between residues 
288-302 in a region of the PHCS molecule which is highly 
flexible,as described by the main chain B-factor values 
shown in fig.7.3. However, their reactivity is greatly 
reduced when PHCS is held in a 'closed' form by bound
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oxaloacetate (section 5.4). This effect may be caused 
solely by a change in the conformation of this epitope 
when oxaloacetate is bound. Alternatively,it may be 
that a reduction in the mobility of this epitope in the 
'closed' form reduces antibody binding efficiency. A 
future study of the kinetics of binding of mAbs B and 
C to PHCS in the 'open' and 'closed' forms described, 
will enable further information to be gained regarding 
the mechanism of antibody-antigen interractions. A 
comparison of the binding affinities of mAbs B and C 
to the synthetic peptide 288-302,with their binding to 
peptides which differ by selected amino-acid substitutions, 
will further the understanding of these interractions.
A long-term project to compare the conformation 
of a synthetic peptide free in solution (from high 
field nuclear magnetic resonance spectroscopic data 
(Dyson et al,1986) with its conformation when bound to 
a mAb (using data from NMR and X-ray crystallography) 
will show the extent of conformational change that an 
antibody confers upon binding to its epitope. If further 
X-ray crystallographic comparisons of the free 'open' 
and 'closed' forms of PHCS with those forms of the 
enzyme once bound by mAbs were performed it would also 













In this appendix chapter I describe some 
preliminary work performed on the ability of mAbs to 
detect citrate synthase in fixed HEp-2 cells. This work 
was performed to show the feasability of the approach, 
and some suggestions are made for further applications.
9.2 Immunofluorescence to show mAb binding to citrate 
synthase
HEp-2 cells a human epithelial cell line,were 
grown on multitest slides,and fixed according to the 
method described in section 3.11. Following incubation 
with mAbs or anti-serum,bound antibodies were detected 
using a fluorescent labelled second antibody,as descr­
ibed in section 3.12.
The reactivities of anti-PHCS antibodies with 
fixed HEp-2 cells is summarised in table 9.1. Only 
cytoplasmic staining was observed. Staining was assessed 
visually and assigned a value of - (negative),+ (weak 
staining) or ++ (strong staining). Figures 9.1,9.2 and
9.3 show examples of the cytoplasmic staining seen with 
normal mouse serum,mAb M and mAb D respectively.
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Table 9.1. Summary of the binding of mAbs and serum




















Assessment of cytoplasmic staining has been 
described in section 9.2.
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Fig. 9.1 Reactivity of normal mouse serum with
fixed HEp-2 cells
a) Immunofluorescent pattern shown under UV light.
b) Cells shown under light microscopy.
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Fig 9.2 Reactivity of mAb M with fixed HEp-2 cells
a) Immunofluorescent pattern shown under UV light.
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Fig. 9.3 Reactivity of mAb D with fixed HEp-2 cells 
a)
a) Immunofluorescent pattern shown under UV light.
198
9.3 Discussion
This work shows that 7 of the 11 mAbs raised 
against PHCS bind to a cytoplasmic component,and can be 
visualised using immunofluorescence. Future work will 
have to prove that the binding of these mAbs is specific, 
to just citrate synthase. Proof of this may be achieved 
by running a cell lysate of HEp-2 cells on a gradient 
SDS-PAGE gel,and immunoblotting with mAbs. This will show 
if mAbs only bind to a lysate component which corresponds 
in molecular weight to citrate synthase.
The KEp-2 cell line is a human cell line. Four 
of the eleven mAbs do not bind to the antigen when assayed 
using immunofluorescence. This may reflect differences in 
the epitopes recognised by these mAbs between the PHCS and 
the human citrate synthase. Alternatively the method of 
antigen fixation may present the epitopes recognised by 
the four mAbs in a form which is no longer capable of 
binding to them.
This study provides preliminary information on 
the possible use of anti-citrate synthase mAbs in 
immunofluorescence experiments which may prove of value 
in further species cross-reactivity experiments.
Using electron-microscopy to study in finer 
detail the binding of mAbs to citrate synthase in fixed 
cells may provide further information on the orientation
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of attachment of the enzyme to membranes. Further .. 
information may also be obtained into the association 
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